UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 001-41323

SOLIDION TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware		87-1993879
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

13355 Noel Rd, Suite 1100 Dallas, TX		75240
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (972) 918-5120

Not applicable

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted and pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		STI		The Nasdaq Stock Market LLC

As of ~~August~~November 1319, 2025, there were 27,~~774~~465,~~305~~283 shares of common stock of of the Company issued and outstanding.

SOLIDION TECHNOLOGY, INC.

FORM 10-Q FOR THE QUARTER ENDED ~~JUNE~~SEPTEMBER 30, 2025

TABLE OF CONTENTS

Part I - FINANCIAL INFORMATION		1
Item 1.	Unaudited Condensed Consolidated and Combined Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3132
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	3738
Item 4.	Controls and Procedures	3738
Part II - OTHER INFORMATION		3940
Item 1.	Legal Proceedings	3940
Item 1A.	Risk Factors	3940
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3940
Item 3.	Defaults Upon Senior Securities	3940
Item 4.	Mine Safety Disclosures	3940
Item 5.	Other Information	3940
Item 6.	Exhibits	4041
SIGNATURES		4142

EXPLANATORY NOTE

On February 2, 2024 (the “Closing Date”), Nubia Brand International Corp., a Delaware corporation (“Nubia” and after the Transactions described herein, the “Combined Company” or “Solidion Technology, Inc.”), consummated the previously announced business combination (the “Closing”) pursuant to a Merger Agreement (as amended on August 25, 2023, the “Merger Agreement”), by and among Nubia, Honeycomb Battery Company, an Ohio corporation (“HBC”), and Nubia Merger Sub, Inc., an Ohio corporation and wholly-owned subsidiary of Nubia (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into HBC (the “Merger,” and the transactions contemplated by the Merger Agreement, the “Transactions”), with HBC surviving such merger as a wholly owned subsidiary of Nubia, which was renamed “Solidion Technology, Inc.” upon Closing.

Unless the context otherwise requires, the “registrant” and the “Company” refer to Nubia prior to the Closing and to the Combined Company and its subsidiaries following the Closing and “HBC” and “Honeycomb” refers to Honeycomb Battery Company and its subsidiaries prior to the Closing and the business of the Combined Company and its subsidiaries following the Closing.

The Company’s common stock, par value $0.0001 per share (the “Common Stock”), is now listed on The Nasdaq Stock Market LLC (“NASDAQ Global”) under the symbol “STI”. The Company’s Public Warrants to purchase Common Stock at an exercise price of $575.00 per share, previously listed under ticker “NUBIW”, were delisted from the Nasdaq and pending listing on The OTC Markets under the symbol “STIWW”. Until the Merger, Nubia neither engaged in any operations nor generated any revenue, and based on its business activities, Nubia was a “shell company” as defined under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

PART I

PART I - FINANCIAL INFORMATION

Item 1. Unaudited Condensed Consolidated and Combined Financial Statements

SOLIDION TECHNOLOGY, INC.

CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS

(unAUDITED)

	June 30, 2025			December 31, 2024
	September 30, 2025			December 31, 2024
ASSETS
Current Assets:
Cash	$	~~114~~160,~~652~~506		$	3,353,732
Accounts receivable		5,~~111~~560			999
Other receivable		302,500			302,500
Inventory		24,430			24,430
Prepaid expenses		~~346~~263,~~237~~899			206,784
Other current assets		~~431~~253,~~608~~887			-
Total Current Assets		1,~~224~~010,~~538~~782			3,888,445
Property and Equipment, net of depreciation		2,~~117~~069,~~196~~620			2,094,536
Patents, net of amortization		12,~~993~~004,~~268~~770			1,972,830
Total Assets	$	5,~~335~~085,~~002~~172		$	7,955,811
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities:
Accounts payable and accrued expenses	$	34,~~457~~240,~~424~~017		$	2,135,586
Income taxes payable		-			6,369
Excise tax payable		~~937~~950,~~167~~815			909,871
Derivative liabilities		1015,~~810~~308,~~700~~400			25,272,650
Due to related party		87,873			87,873
Convertible notes		-			527,500
Short-term notes payable		1,~~875~~905,~~290~~067			1,917,962
Total Liabilities		1722,~~168~~492,~~454~~172			30,857,811
Commitments and contingencies (Note 5)
Stockholders’ Equity (Deficit):
Preferred stock, $0.0001 par value; 2,000,000 shares authorized; none issued and outstanding		-			-
Common stock, $0.0001 par value, 300,000,000 shares authorized, 2,716,794 and 2,633,956 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively		272			13,169
Common stock, $0.0001 par value, 300,000,000 shares authorized, 2,874,326 and 2,633,956 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively		288			13,169
Additional paid-in capital		9495,~~785~~564,~~605~~836			93,045,581
Stock subscription receivable		(80,241	)		(80,241	)
Accumulated deficit		(~~106~~112,~~539~~891,~~088~~883	)		(115,880,509	)
Total Stockholders’ Equity (Deficit)		(1117,~~833~~407,~~452~~000	)		(22,902,000	)
Total Liabilities and Stockholders’ Equity (Deficit)	$	5,~~335~~085,~~002~~172		$	7,955,811

The accompanying notes are an integral part of these unaudited condensed consolidated and combined financial statements.

SOLIDION TECHNOLOGY, INC.

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS

(unAUDITED)

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2025			2024			2025			2024 (Restated)
Net sales	$	49,~~000~~350			-		$	413,~~000~~350			-
Cost of goods sold		24,~~327~~321			-			26,~~327~~648			-
Gross profit		15,~~673~~029			-			16,~~673~~702			-
Operating Expenses
Research and development		~~399~~523,~~542~~569			~~400~~459,~~658~~805			12,~~752~~276,~~592~~161			1,~~129~~589,~~772~~577
Selling, general and administrative		1,~~389~~224,~~255~~360			23,~~532~~733,~~651~~201			34,~~168~~393,~~874~~234			59,~~562~~296,~~873~~074
Total operating expenses		1,~~788~~747,~~797~~929			24,~~933~~193,~~309~~006			46,~~921~~669,~~466~~395			610,~~692~~885,~~645~~651
Operating loss		(1,~~787~~742,~~124~~900	)		(24,~~933~~193,~~309~~006	)		(46,~~919~~662,~~793~~693	)		(610,~~692~~885,~~645~~651	)
Other Income (Expense)
Change in fair value of derivative liabilities		(2,~~044~~237,~~500~~050	)		247,~~966~~232,~~700~~835			149,~~461~~964,~~950~~250			1624,~~784~~017,~~200~~035
Issuance of common stock and warrants		-			-(9,654,799	)		-			(2030,~~590~~245,~~717~~516	)
Interest income		~~1,886~~176			~~171~~1,573			18,~~157~~333			~~482~~2,055
Interest expense		(112,~~471~~371	)		(1922,~~184~~910	)		(~~218~~331,~~893~~264	)		(2245,~~923~~833	)
Other income (expense)		-			~~4,038~~(372	)		-			43,~~037~~665
Total other income (expense)		1(2,~~933~~349,~~915~~245	)		24(2,~~951~~443,~~725~~673	)		149,~~261~~651,~~214~~319			(36,~~824~~268,~~921~~594	)
Net income (loss) before provision for income taxes		~~146~~(4,~~791~~092,145	)		22(6,~~018~~636,~~416~~679	)		92,~~341~~988,~~421~~626			(1017,~~517~~154,~~566~~245	)
Provision for income taxes		-			-			-			-
Net Income (loss)	$	~~146~~(4,~~791~~092,145	)	$	22(6,~~018~~636,~~416~~679	)	$	92,~~341~~988,~~421~~626		$	(1017,~~517~~154,~~566~~245	)
Weighted average number of shares of common stock outstanding, basic		3,~~002~~076,~~802~~486			12,~~805~~056,~~261~~172			3,~~002~~027,~~295~~298			1,~~695~~816,~~155~~372
Basic net income (loss) per share of common stock	$	0(1.0533	)	$	12(3.2023	)	$	30.1199		$	(69.2044	)
Weighted average number of shares of common stock outstanding, diluted		3,~~197~~076,~~385~~486			12,~~923~~056,~~190~~172			34,~~484~~999,~~059~~099			1,~~695~~816,~~155~~372
Diluted net income (loss) per share of common stock	$	0(1.0533	)	$	11(3.4523	)	$	20.6860		$	(69.2044	)

The accompanying notes are an integral part of these unaudited condensed consolidated and combined financial statements.

SOLIDION TECHNOLOGY, INC.

CONDENSED Consolidated AND COMBINED STATEMENTS OF CHANGES IN STOCKHOLDERs’ (DEFICIT) EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025

	Three Months Ended September 30, 2025
					Additional					Stock			Stockholders’
	Common Stock				Paid-in		Accumulated			Subscription			Equity
	Shares		Amount		Capital		Deficit			Receivable			(Deficit)
Balance at June 30, 2025		2,716,794	$	272	$	94,785,605	$	(108,799,738	)	$	(80,241	)	$	(14,094,102	)
Shares issued from exercise of Series A Warrants		157,532		16		430,006		—			—			430,022
Stock-based compensation		—		—		349,225		—			—			349,225
Net income (loss)		—		—		—		(4,092,145	)		—			(4,092,145	)
Balance at September 30, 2025		2,874,326	$	288	$	95,564,836	$	(112,891,883	)	$	(80,241	)	$	(17,407,000	)

(UNAUDITED)

	Nine Months Ended September 30, 2025
							Additional					Stock			Stockholders’
	Common Stock						Paid-in		Accumulated			Subscription			Equity
	Shares			Amount			Capital		Deficit			Receivable			(Deficit)
Balance at December 31, 2024		2,633,956		$	13,169		$	93,045,581	$	(115,880,509	)	$	(80,241	)	$	(22,902,000	)
Shares issued from exercise of Series A Warrants		172,287			90			671,478		—			—			671,568
Conversion of convertible notes into common stock		68,095			339			527,161		—			—			527,500
Shares issued to consultants		100			1			670		—			—			671
Reverse stock split		(112	)		(13,311	)		12,851		—			—			(460	)
Stock-based compensation		—			—			1,307,095		—			—			1,307,095
Net income (loss)		—			—			—		2,988,626			—			2,988,626
Balance at September 30, 2025		2,874,326		$	288		$	95,564,836	$	(112,891,883	)	$	(80,241	)	$	(17,407,000	)

							Additional						Stock			Stockholders’
	Common Stock						Paid-in			Accumulated			Subscription			Equity
	Shares			Amount			Capital			Deficit			Receivable			(Deficit)
Balance at December 31, 2024		2,633,956		$	13,169		$	93,045,581		$	(115,880,509	)	$	(80,241	)	$	(22,902,000	)
Shares issued from exercise of Series A Warrants		14,755			74			241,472			—			—			241,546
Conversion of convertible notes into common stock		67,895			339			527,161			—			—			527,500
Shares issued to consultants		100			1			670			—			—			671
Reverse stock split		—			(13,311	)		13,311			—			—			—
Stock-based compensation		—			—			754,361			—			—			754,361
Net income (loss)		—			—			—			9,194,630			—			9,194,630
Balance at March 31, 2025		2,716,706		$	272		$	94,582,556		$	(106,685,879	)	$	(80,241	)	$	(12,183,292	)
Conversion of convertible notes into common stock		200			—			—			—			—			—
Reverse stock split		(112	)		—			(460	)		—			—			(460	)
Stock-based compensation		—			—			203,509			—			—			203,509
Net income (loss)		—			—			—			146,791			—			146,791
Balance at June 30, 2025		2,716,794		$	272		$	94,785,605		$	(106,539,088	)	$	(80,241	)	$	(11,833,452	)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024

(RESTATED)

					Additional						Stock			Stockholders’
	Common Stock				Paid-in			Accumulated			Subscription			Equity
	Shares		Amount		Capital			Deficit			Receivable			(Deficit)
Balance at December 31, 2023		—	$	—	$	28,857,965		$	(25,445,506	)	$	—		$	3,412,459
Retroactive application of recapitalization to December 31, 2023		1,396,000		6,980		(6,980	)		—			—			—
Adjusted beginning balance		1,396,000		6,980		28,850,985			(25,445,506	)		—			3,412,459
Balance at January 1, 2024, after retroactive application of recapitalization		1,396,000		6,980		28,850,985			(25,445,506	)		—			3,412,459
Capital contributions from related party		—		—		487,273			—			—			487,273
Issuance of common stock upon consummation of the Merger		120,093		600		(27,888,519	)		—			—			(27,887,919	)
Conversion of convertible notes into common stock upon consummation of the Merger		119,245		596		3,174,404			—			—			3,175,000
Stock subscription receivable		—		—		—			—			(80,241	)		(80,241	)
Earnout Arrangement		—		—		63,600,000			(63,600,000	)		—			—
Contingent consideration		—		—		906,000			(906,000	)		—			—
Convertible note – stock issuance loss		—		—		2,769,719			—			—			2,769,719
Private Placement		102,667		513		8,931,484			—			—			8,931,997
Issuance costs in connection with the Private Placement		—		—		(262,064	)		—			—			(262,064	)
Stock-based compensation		—		—		1,359,000			—			—			1,359,000
Net loss		—		—		—			(32,535,982	)		—			(32,535,982	)
Balance at March 31, 2024		1,738,005	$	8,689	$	81,928,282		$	(122,487,488	)	$	(80,241	)	$	(40,630,758	)
Shares issued from exercise of Series B Warrants		3,999		20		14			—			—			34
Stock-based compensation		—		—		451,662			—			—			451,662
Net loss		—		—		—			22,018,416			—			22,018,416
Balance at June 30, 2024		1,742,004	$	8,709	$	82,379,958		$	(100,469,072	)	$	(80,241	)	$	(18,160,646	)

The accompanying notes are an integral part of these unaudited condensed consolidated and combined financial statements.

SOLIDION TECHNOLOGY, INC.

CONDENSED Consolidated AND COMBINED STATEMENTS OF CHANGES IN STOCKHOLDERs’ (DEFICIT) EQUITY

	Three Months Ended September 30, 2024
					Additional						Stock			Stockholders’
	Common Stock				Paid-in			Accumulated			Subscription			Equity
	Shares		Amount		Capital			Deficit			Receivable			(Deficit)
Balance at June 30, 2024		1,742,004	$	8,709	$	82,379,958		$	(100,469,072	)	$	(80,241	)	$	(18,160,646	)
Shares issued from exercise of Series A Warrants		9,320		47		162,007			—			—			162,054
Shares issued from exercise of Series B Warrants		103,282		516		1,370			—			—			1,886
Issuance of common stock for Forward Purchase Agreement		190,860		954		(954	)		—			—			—
Issuance of common stock for Forward Purchase Agreement Compensation		57,000		285		1,025,715			—			—			1,026,000
Private Placement		244,349		1,222		3,998,778			—			—			4,000,000
Stock-based compensation to consultant		—		—		700,000			—			—			700,000
Issuance costs in connection with the Private Placement		—		—		(157,435	)		—			—			(157,435	)
Stock-based compensation		—		—		278,176			—			—			278,176
Net Loss		—		—		—			(6,636,679	)		—			(6,636,679	)
Balance at September 30, 2024		2,346,815		11,733		88,387,615			(107,105,751	)	$	(80,241	)		(18,786,644	)

	Nine Months Ended September 30, 2024 (Restated)
					Additional						Stock			Stockholders’
	Common Stock				Paid-in			Accumulated			Subscription			Equity
	Shares		Amount		Capital			Deficit			Receivable			(Deficit)
Balance at December 31, 2023		—	$	—	$	28,857,965		$	(25,445,506	)		—		$	3,412,459
Retroactive application of recapitalization to December 31, 2023		1,396,000		6,980		(6,980	)		—			—			—
Adjusted beginning balance		1,396,000		6,980		28,850,985			(25,445,506	)		—			3,412,459
Balance at January 1, 2024, after retroactive application of recapitalization		1,396,000		6,980		28,850,985			(25,445,506	)		—			3,412,459
Capital contributions from related party		—		—		487,273			—			—			487,273
Issuance of common stock upon consummation of the Merger		120,093		600		(27,888,519	)		—			—			(27,887,919	)
Conversion of convertible notes into common stock upon consummation of the Merger		119,245		596		3,174,404			—			—			3,175,000
Stock subscription receivable		—		—		—			—			(80,241	)		(80,241	)
Earnout Arrangement		—		—		63,600,000			(63,600,000	)		—			—
Contingent consideration		—		—		906,000			(906,000	)		—			—
Convertible note – stock issuance loss		—		—		2,769,719			—			—			2,769,719
Shares issued from exercise of Series A Warrants		9,320		47		162,007			—			—			162,054
Shares issued from exercise of Series B Warrants		107,281		536		1,384			—			—			1,920
Issuance of common stock for Forward Purchase Agreement		190,860		954		(954	)		—			—			—
Issuance of common stock for Forward Purchase Agreement Compensation		57,000		285		1,025,715			—			—			1,026,000
Private Placements		347,016		1,735		12,930,262			—			—			12,931,997
Stock-based compensation to consultant		—		—		700,000			—			—			700,000
Issuance costs in connection with the Private Placement		—		—		(419,499	)		—			—			(419,499	)
Stock-based compensation		—		—		2,088,838			—			—			2,088,838
Net Loss		—		—		—			(17,154,245	)		—			(17,154,245	)
Balance at September 30, 2024		2,346,815		11,733		88,387,615			(107,105,751	)	$	(80,241	)		(18,786,644	)

The accompanying notes are an integral part of these unaudited condensed consolidated and combined financial statements.

SOLIDION TECHNOLOGY, INC.

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS

(UNAUdITED)

	For the Six Months Ended June 30,
	For the Nine Months Ended September 30,
	2025			2024 (Restated)
Cash Flows From Operating Activities:
Net income (loss)	$	92,~~341~~988,~~421~~626		$	(1017,~~517~~154,~~566~~245	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization		~~138~~206,~~400~~858			~~197~~298,~~303~~805
Stock based compensation		~~957~~1,~~869~~307,095			12,~~810~~088,~~662~~838
Equity compensation expense		671			—1,726,000
Non-cash interest expense		202,920			—
Change in fair value of derivative liabilities		(9,964,250	)		(24,017,035	)
Change in fair value of derivative liabilities		(14,461,950	)		(16,784,200	)
Issuance of common stock and warrants		—			30,245,516
Issuance of common stock and warrants		—			20,590,717
Changes in operating assets and liabilities:
Accounts receivable		(4,~~112~~561	)		1,~~164~~165
Other receivable		—			(115,000	)
Inventory		—			(1,700	)
Prepaid expenses		(~~139~~57,~~453~~115	)		~~(57~~46,~~418~~492	)
Other current assets		(~~431~~253,~~608~~887	)		(~~777~~356,~~135~~301	)
Other non-current assets		—			(778,167	)
Accounts payable and accrued expenses		2,134,207			1,560,273
Accounts payable and accrued expenses		1,118,918			2,889,968
Income taxes payable		(6,369	)		—
Excise taxes		2740,~~296~~944			—
Net Cash Used In Operating Activities		(3,~~255~~607,~~997~~781	)		(35,~~541~~677,~~372~~192	)
Cash Flows From Investing Activities:
Purchases of property and equipment		(117,812	)		—
Capitalized patent costs		(6396,~~686~~070	)		(~~157~~190,~~834~~931	)
Net Cash Used In Investing Activities		(~~181~~213,~~498~~882	)		(~~157~~190,~~834~~931	)
Cash Flows From Financing Activities:
Capital contributions from Global Graphene Group		—			487,273
Cash received from NUBI Trust		—			25,160,047
Discount payment related to Non Redemption Agreement		—			(13,937,997	)
Reimbursement of consideration shares related to the Forward Purchase Agreement		—			(2,193,800	)
Reimbursement of Recycled Shares related to Forward Purchase Agreement		—			(80,241	)
Transaction expenses in connection with the Merger		—			(8,948,009	)
Inflow from Merger		—			17,555
Proceeds from convertible notes		—			527,500
Proceeds from short-term notes		—			670,000
Repayment of short-term notes		(42,671	)		(~~424~~1,~~277~~329,712	)
Proceeds from issuance of common stock and warrants in connection with the Private Placement		—			37,850,000
Proceeds from issuance of common stock from exercise of warrants		~~241~~671,~~546~~568			34163,974
Issuance costs in connection with the Private Placement		—			(~~262~~419,~~064~~499	)
Repayment of related party payable		—			(911,091	)
Cash used to settle fractional shares		(460	)		—
Net Cash Provided By Financing Activities		~~198~~628,~~415~~437			37,~~954~~056,~~930~~000
Net change in cash		(3,~~239~~193,~~080~~226	)		~~255~~1,~~724~~187,877
Cash at beginning of period		3,353,732			780
Cash at end of period	$	~~114~~160,~~652~~506		$	~~256~~1,~~504~~188,657
Supplemental disclosure
Cash paid for interest expense	$	716,~~329~~627		$	89153,~~012~~128
Cash paid for federal income taxes	$	6,369		$	—
Supplemental disclosure of non-cash financing activities:
Issuance of Common Stock upon the closing of the Merger	$	~~414~~—		$	12,~~216~~435
Convertible notes converted to common shares	$	527,500		$	—
Capitalized interest to principal balance of short-term note payable	$	202,920		$	—
Reverse stock split — reclassification from common stock to additional paid-in capital	$	13,311		$	—

The accompanying notes are an integral part of these unaudited condensed consolidated and combined financial statements.

SOLIDION TECHNOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 — DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

Solidion Technology, Inc (the “Company”, “Solidion” or “Solidion Technology”), formerly known as Nubia Brand International Corp. prior to February 2, 2024, was incorporated in Delaware on June 14, 2021 and is an advanced battery technology company focused on the development and commercialization of next-generation battery materials, components, and energy storage solutions. Solidion is headquartered in Dallas, TX, with research and development and manufacturing operations located in Dayton, OH.

On February 2, 2024, Nubia Brand International Corp., a Delaware corporation (“Nubia” and after the Transactions described herein, the “Company”, “Solidion” or “Solidion Technology, Inc.”), consummated the merger (the “Closing”) pursuant to a Merger Agreement, dated February 16, 2023 (as amended on August 25, 2023, the “Merger Agreement”), by and among Nubia, Honeycomb Battery Company, an Ohio corporation (“HBC”), and Nubia Merger Sub, Inc., an Ohio corporation and wholly-owned subsidiary of Nubia (“Merger Sub”). HBC was formerly the energy solutions division of Global Graphene Group, Inc. (“G3”). Pursuant to the Merger Agreement, Merger Sub merged with and into HBC (the “Merger,” and the transactions contemplated by the Merger Agreement, the “Transactions”), with HBC surviving such merger as a wholly owned subsidiary of Nubia, which was renamed “Solidion Technology, Inc.” upon Closing.

In accordance with the Merger Agreement the Company issued to the HBC stockholders aggregate consideration of 1,400,000 shares of Solidion’s common stock, minus up to 4,000 Holdback Shares, subject to adjustment for any additional interest or penalties related to the G3 Tax Lien (the “Closing Merger Consideration Shares”) at the effective time of the Merger Agreement (the “Effective Time”), plus up to an additional 450,000 shares of Solidion’s common stock (the “Earnout Shares”) upon the occurrence of the following events (or earlier upon a change of control of Solidion but subject to (and only to the extent that) the valuation of Solidion’s common stock implied by such change of control transaction meeting the respective volume weighted average price (“VWAP”), as defined in the Merger Agreement, thresholds set forth below) (the “Earnout Arrangement”):

(i) 100,000 Earnout Shares if, over any ten (10) trading days within any thirty (30) trading day period from and after the date that is thirty (30) days following the closing date of the Transactions (the “Closing Date”) until the second anniversary of the Closing Date, the VWAP of the shares of Solidion’s Class A common stock is greater than or equal to $12625.5000 per share (subject to any adjustment pursuant to the Merger Agreement);

(ii) 150,000 Earnout Shares if, over any ten (10) trading days within any thirty (30) trading day period from and after the date that is one hundred eighty (180) days following the Closing Date until the date that is forty-two (42) months following the Closing Date, the VWAP of the shares of Solidion’s Class A common stock is greater than or equal to $15750.00 per share (subject to any adjustment pursuant to the Merger Agreement); and

(iii) 200,000 Earnout Shares if over any ten (10) trading days within any thirty (30) trading day period from and after the date that is one hundred eighty (180) days following the Closing Date until the fourth anniversary of the Closing Date, the VWAP of the shares of Solidion’s Class A common stock is greater than or equal to $251250.00 per share (subject to any adjustment pursuant to the Merger Agreement).

If, prior to the expiration of the earn out periods set forth in (i)-(iii) above, there occurs any transaction resulting in a change in control, and the corresponding valuation of Solidion’s Class A common stock, calculated inclusive of the Earnout Shares to be issued under the Earnout Arrangement, is greater than or equal to the amount set forth in (i)-(iii), as applicable, then, immediately prior to the consummation of such change in control, the event set forth in (i)-(iii), as applicable, if not previously satisfied, shall be deemed to have occurred, subject to the terms provided in the Merger Agreement.

As of ~~June~~September 30, 2025, none of the Earnout ~~Shares~~ Shares had been earned by G3.

5On October 9, 2025, the Company issued 450,000 shares of its common stock to G3 pursuant to the earnout provisions of the Merger Agreement. These shares represent the full amount of the Earnout Shares described above.

The issuance followed the approval of the Company’s Board of Directors to deem all earnout milestones satisfied in full, after considering the Company’s post-merger capital structure and ongoing shared-services arrangements with G3. Accordingly, the Company has completed its obligations related to the Earnout Arrangement under the Merger Agreement.

The Merger was accounted for as a common control transaction with respect to HBC which is akin to a reverse recapitalization. This conclusion was based on the fact that G3 had a controlling financial interest in HBC prior to the Merger and has a controlling financial interest in Solidion (which includes HBC as a wholly owned subsidiary). Net assets of Nubia were stated at their historical carrying amounts with no goodwill or intangible assets recognized in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Merger with respect to HBC was not treated as a change in control due primarily to G3 receiving the controlling voting stake in Solidion and G3’s ability to nominate a majority of the board of directors of Solidion. Under the guidance in ASC 805 for transactions between entities under common control, the assets and liabilities of HBC and Nubia are recognized at their carrying amounts on the date of the Merger.

Under a reverse recapitalization, Nubia was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of HBC issuing stock for the net liabilities of Nubia, accompanied by a recapitalization.

Going Concern

The Company’s financial statements have been prepared under the assumption that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business for the foreseeable future.

Since the Company’s inception, it has experienced recurring net losses and net cash used in operating activities and has generated minimal sales. For the ~~six~~nine months ended ~~June~~September 30, 2025, the Company recorded a net income of $92,~~341~~988,~~421~~626, which included a gain of $149,~~461~~964,~~950~~250 due to the change in the fair value of derivative liabilities, net cash used in operating activities of $3,~~255~~607,~~997~~781 and as of ~~June~~September 30, 2025, had cash and cash equivalents of $~~114~~160,~~652~~506. ~~For~~ For the year ended December 31, 2024, the Company recorded a net loss of $25,929,003, which included a gain of $18,011,100 due to the ~~change~~ change in the fair value of derivative liabilities and a $30,281,475 loss due to the issuance of common stock and warrants, net cash used in in operating activities of $7,377,807 and as of December 31, 2024, had cash and cash equivalents of $3,353,732.

The Company expects to continue to incur net losses and net cash used in operating activities in accordance with its operating plan and expects that expenditures will increase significantly in connection with its ongoing activities. As of the balance sheet date and up to the date that the financial statements were issued, the Company does not have availability under any debt agreements. Additionally, the Company is currently in default of an outstanding Promissory Note due to non-payment of scheduled installments. Given the Company’s projected operating requirements and its existing cash and cash equivalents, the Company is projecting insufficient liquidity to sustain its operations and meet its obligations through one year following the date that the financial statements were issued. This raises substantial doubt about the Company’s ability to continue as a going concern.

In addition, the Company has received a notice from the Nasdaq related to their failure to maintain the minimum bid price requirement of $1 per share. In response, on May 12, 2025, the Company effectuated a 1-for-50 reverse split of its Common Stock in order to reach the Nasdaq minimum. The primary objective of the reverse stock split is to increase the per-share market price of the Company'’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq. Additionally, on April, 16, 2025, the Company received notice from the Nasdaq due to the Company’s noncompliance with Nasdaq’s minimum Market Value of Listed Securities (“MVLS”) requirement and minimum Market Value of Publicly Held Shares (“MVPHS”) requirement. The Company has a compliance period of 180 calendar days, or until October 13, 2025, to regain compliance with the MVPHS requirement.

On July 7, 2025, the Company received notice from Nasdaq that it has regained compliance with Listing Rule 5450(a)(1) (the “Bid Price Rule”).

AsPrior ofto the ~~date~~expiration of ~~this~~the ~~filing~~180-day compliance periods related to Nasdaq’s MVLS and MVPHS requirements, the Company isapplied for a transfer of the listing of its securities to The Nasdaq Capital ~~not~~Market. ~~currently~~On inOctober ~~compliance~~29, ~~with~~2025 the Company was notified by Nasdaq staff that Company’s ~~MVLS~~application ~~listing~~to ~~rules~~list ~~and~~its ifCommon ~~the~~Stock on The Nasdaq Capital Market was approved. The Company’s ~~does~~securities ~~not~~were ~~regain~~transferred ~~compliance,~~to the ~~common~~Capital ~~stock of~~Market at the ~~Company~~opening ~~could~~of bebusiness ~~delisted~~on October ~~from~~31, ~~the~~2025. ~~Nasdaq~~As ~~exchange~~a result, all matters pertaining to MVLS and MVPHS requirements are now closed.

IfOn September 8, 2025, the Company’s ~~common~~notified ~~stock~~Nasdaq that, isfollowing ~~delisted, it~~the ~~may~~resignation ~~affect~~of ~~the~~a ~~Company’s~~director ~~ability~~on toSeptember ~~obtain~~3, ~~financing~~2025, ~~trade~~its orAudit ~~sell~~Committee ~~shares~~was ofno ~~their~~longer ~~common~~in ~~stock,~~compliance ~~and/or~~with ~~forecasted~~Nasdaq ~~operations~~Listing ~~could~~Rule be5605(c)(2)(A), ~~negatively~~which ~~impacted~~requires inlisted companies to maintain an ~~amount~~audit ~~that~~committee consisting of at least three independent directors. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company ~~cannot~~is ~~currently~~entitled ~~quantify.~~to ~~These~~a ~~events~~cure ~~and~~period ~~conditions~~to ~~raise~~regain ~~substantial~~compliance, ~~doubt~~which extends until ~~about~~the earlier of (i) the Company’s ~~ability~~next toannual ~~continue~~meeting asof ashareholders ~~going~~or ~~concern~~(ii) September 3, 2026; provided, however, that if the annual meeting occurs on or before March 2, 2026, the cure period will extend only until March 2, 2026.

The Company intends to appoint an additional independent director to the Audit Committee as soon as practicable within the applicable cure period. Failure to regain compliance within the prescribed timeframe could result in Nasdaq initiating delisting proceedings. While the Company believes it will successfully cure this deficiency, the need to regain compliance within a limited timeframe represents an additional uncertainty that management has considered in its assessment of the Company’s ability to continue as a going concern.

As an early-stage growth company, the Company’s ability to access capital is critical. The Company plans to finance its operations with proceeds from the sale of equity securities or debt; however, there is no assurance that management’s plans to obtain additional debt or equity financing will be successfully implemented or implemented on terms favorable to the Company.

The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Risks and Uncertainties

The Company’s current business activities consist of development and commercialization of battery materials, components, cells, and selected module/pack technologies. The Company faces inherent risks associated with its operations, such as the ongoing development of its technology, marketing, and distribution channels, as well as the enhancement of its supply chain and manufacturing capabilities. Additionally, the need to recruit additional management and key personnel is vital. The success of the Company’s development initiatives and the achievement of profitability hinge on various factors, including its ability to enter potential markets and secure sustainable financing in the future.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, competition from substitute products and larger companies, protection of proprietary technology, ability to maintain distributor relationships and dependence on key individuals.

6NOTE 2 — CORRECTION OF ERRORS IN PREVIOUSLY REPORTED CONDENSED CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS

NOTE 2 — CORRECTION OF ERRORS IN PREVIOUSLY REPORTED CONSOLIDATED FINANCIAL STATEMENTS

Subsequent to the issuance of the interim financial information as of and for the period ended September 30, 2024, the Company identified an error related to the accounting for issuance costs associated with convertible notes. Specifically, approximately $2.8 million of non-cash, non-operating stock-based expense related to bonus shares was inadvertently omitted and not reflected in the financial statements for the first quarter of 2024. See Note 10 Convertible Notes for more details.

As a result, the Company has revised its previously issued financial statements to reflect the correction of this material error, recording the issuance cost in issuance of common stock and warrants within non-operating losses. The revision had no impact on total stockholders’ equity or cash flows, but it did increase net loss and increase additional paid-in capital in the affected periods.

The revised quarterly financial information is included in this Quarterly Report on Form 10-Q in the tables that follow.

All references to common stock, warrants, and restricted stock units, as well as related per-share amounts in these condensed consolidated and combined financial statements, have been retrospectively adjusted to reflect the 1-for-50 reverse stock split effected on May 12, 2025.

The impact of the restatement on the condensed consolidated and combined statement of operations for the ~~six~~nine months ended ~~June~~September 30, 2024 is as follows:

	June 30, 2024 (Unaudited)
	For the Nine Months EndedSeptember 30, 2024 (Unaudited)
	As Reported			Adjustments				As Restated
OTHER INCOME (EXPENSE)
Change in fair value of derivative liabilities	$	1624,~~784~~017,~~200~~035		$	-		$	$	1624,~~784~~017,~~200~~035
Issuance of Common Stock and Warrants		(1727,~~820~~475,~~998~~797	)		(2,769,719	)			(2030,~~590~~245,~~717~~516	)
Interest income		~~482~~2,055			-				~~482~~2,055
Interest expense		(2245,~~923~~833	)		-				(2245,~~923~~833	)
Other income (expense)		43,~~037~~665			-				43,~~037~~665
Total other expense		(13,~~055~~498,~~202~~875	)		(2,769,719	)			(36,~~824~~268,~~921~~594	)
Net loss before income tax provision		(714,~~747~~384,~~847~~526	)		(2,769,719	)			(1017,~~517~~154,~~566~~245	)
Income tax provision		-			-				-
Net loss	$	(714,~~747~~384,~~847~~526	)	$	(2,769,719	)	$	$	(1017,~~517~~154,~~566~~245	)
Weighted average shares outstanding, basic and diluted		1,~~651~~764,~~120~~630			4451,~~035~~742				1,~~695~~816,~~155~~372
Basic and diluted net loss per share	$	(48.6915	)	$	(1.5129	)	$	$	(69.2044	)

The impact of the restatement on the condensed consolidated and combined statement of changes in stockholders’ (deficit) equity for the six months ended June 30, 2024 is as follows:

	Six Months Ended June 30, 2024 (Unaudited)
	Additional					Stockholders’
	Paid-in		Accumulated			Equity
	Capital		Deficit			(Deficit)
As Reported
Balance at January 1, 2024, after retroactive application of recapitalization	$	28,850,985	$	(25,445,506	)	$	3,412,459
Convertible note – stock issuance loss		—		—			—
Net Loss		—		(7,747,847	)		(7,747,847	)
Balance at June 30, 2024		79,610,239		(97,699,353	)		(18,160,646	)
Adjustments
Balance at January 1, 2024, after retroactive application of recapitalization		—		—			—
Convertible note – stock issuance loss	$	2,769,719	$	—		$	2,769,719
Net Loss		—		(2,769,719	)		(2,769,719	)
Balance at June 30, 2024	$	2,769,719	$	(2,769,719	)	$	—
As Restated
Balance at January 1, 2024, after retroactive application of recapitalization	$	28,850,985	$	(25,445,506	)	$	3,412,459
Convertible note – stock issuance loss		2,769,719		—			2,769,719
Net Loss		—		(10,517,566	)		(10,517,566	)
Balance at June 30, 2024	$	82,379,958	$	(100,469,072	)	$	(18,160,646	)

The impact of the restatement on the condensed consolidated and combined statement of cash flows for the six months ended June 30, 2024 is as follows:

	June 30, 2024 (Unaudited)
	As Reported			Adjustments			As Restated
Cash Flows From Operating Activities:
Net income (loss)	$	(7,747,847	)	$	(2,769,719	)	$	(10,517,566	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and Amortization expense		197,303			-			197,303
Stock-based compensation		1,810,662			-			1,810,662
Change in fair value of derivative liabilities		(16,784,200	)		-			(16,784,200	)
Loss on issuance of common stock and warrants		17,820,998			2,769,719			20,590,717

There was no impact on net cash used in operating activities or within any line items within investing and financing activities.

The impact of the restatement on the condensed consolidated and combined statement of changes in stockholders’ (deficit) equity for the nine months ended September 30, 2024 is as follows:

	For the Nine Months Ended September 30, 2024 (Unaudited)
	Additional					Stockholders’
	Paid-in		Accumulated			Equity
	Capital		Deficit			(Deficit)
As Reported
Balance at January 1, 2024, after retroactive application of recapitalization	$	28,850,985	$	(25,445,506	)	$	3,412,459
Convertible note – stock issuance loss		—		—			—
Net Loss		—		(14,384,526	)		(14,384,526	)
Balance at September 30, 2024		85,617,896		(104,336,032	)		(18,786,644	)

Adjustments
Balance at January 1, 2024, after retroactive application of recapitalization		—		—			—
Convertible note – stock issuance loss	$	2,769,719	$	—		$	2,769,719
Net Loss		—		(2,769,719	)		(2,769,719	)
Balance at September 30, 2024	$	2,769,719	$	(2,769,719	)	$	—

As Restated
Balance at January 1, 2024, after retroactive application of recapitalization	$	28,850,985	$	(25,445,506	)	$	3,412,459
Convertible note – stock issuance loss		2,769,719		—			2,769,719
Net Loss		—		(17,154,245	)		(17,154,245	)
Balance at September 30, 2024	$	88,387,615	$	(107,105,751	)	$	(18,786,644	)

The impact of the restatement on the condensed consolidated and combined statement of cash flows for the nine months ended September 30, 2024 is as follows:

	For the Nine Months Ended September 30, 2024 (Unaudited)
	As Reported			Adjustments			As Restated
Cash Flows From Operating Activities:
Net income (loss)	$	(14,384,526	)	$	(2,769,719	)	$	(17,154,245	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and Amortization expense		298,805			-			298,805
Stock-based compensation		2,088,838			-			2,088,838
Equity compensation expense		1,726,000			-			1,726,000
Change in fair value of derivative liabilities		(24,017,035	)		-			(24,017,035	)
Loss on issuance of common stock and warrants		27,475,797			2,769,719			30,245,516

There was no impact on net cash used in operating activities or within any line items within investing and financing activities.

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated and combined financial statements (the “financial statements”) are presented in conformity with US GAAP and pursuant to the rules and regulations of the SEC.

During the periods prior to the Closing date of the Merger, the Company operated as part of G3. Consequently, stand-alone financial statements have not historically been prepared for the Company. The accompanying financial statements have been prepared from G3’s historical accounting records and are presented on a stand-alone basis as if the Company’s operations had been conducted independently from G3. Therefore, the financial statements included herein may not be indicative of the financial position, results of operations, and cash flows of the Company in the future or if the Company had been a separate, stand-alone entity during the periods presented.

The Company’s financial statements have been prepared under the assumption that the Company will continue as a going concern, which contemplates the realization of assets and discharge of liabilities in the normal course of business for the foreseeable future.

The financial statements include the Company entities. All intercompany transactions have been eliminated for consolidation purposes.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

910

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the balance sheet which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Segment Reporting

The Company has determined that the Chief Executive Officer is its Chief Operating Decision Maker (the “CODM”). Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined that it operates in one operating segment and one reportable segment, as the CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.

The CODM uses consolidated net income (loss) as the measure of segment profit or loss. Expense information is also reviewed only at the consolidated level, as presented in the Company’s consolidated statement of operations. Research and development expense has been identified as a significant segment expense, with all other expense lines being considered part of ‘Other segment items.’ Additionally, the CODM evaluates assets on a consolidated basis. As such, the Company reports segment profit or loss, segment expenses, and segment assets on a consolidated and combined basis.

Cash and cash equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of ~~June~~September 30, 2025 and December 31, 2024.

Accounts Receivable, net of Allowance for Credit Losses

Accounts receivables are stated at the amount the Company expects to collect. The Company recognizes an allowance for credit losses to ensure accounts receivables are not overstated due to un-collectability. Bad debt reserves are maintained as warranted for various customers based on a variety of factors, including the length of time the receivables are past due, significant one-time events and historical experience. An additional reserve for individual accounts is recorded when the Company becomes aware of a customer’s inability to meet its financial obligation, such as in the case of bankruptcy filings, or deterioration in such customer’s operating results or financial position. If circumstances related to a customer change, estimates of the recoverability of receivables would be further adjusted. As of ~~June~~September 30, 2025 and December 31, 2024, the Company determined that no allowance was required.

Other Receivable

During the first quarter of 2024, the Company advanced $302,500 to G3 for transaction costs incurred during the Merger. As of ~~June~~September 30, 2025 and December 31, 2024, the outstanding ~~balance~~ balance of other receivables amounted to $302,500.

Inventory

Inventories are stated at the lower of first-in, first-out cost or net realizable value. The Company writes-down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. The Company writes off obsolete inventories when the Company deems the value to be impaired. As of ~~June~~September 30, 2025 and December 31, 2024, the Company determined that no write off was required.

1011

Property and Equipment, net

Property and equipment are recorded at cost less accumulated depreciation. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life, are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized. The Company assesses the carrying value of its property and equipment for impairment each year and when indicators exist that there could be an impairment.

Based on its assessments, the Company did not incur any impairment charges for the three and ~~six~~nine months ended ~~June~~September 30, 2025 and for the year ended December 31, 2024.

The Company depreciates its property and equipment for financial reporting purposes using the straight-line method over the estimated useful lives of the assets. The estimated useful lives are as follows:

Building		40 years
Building improvements		15 years
Machinery & equipment		5 years

Depreciation expense of property and equipment was $47,576, $95142,~~152~~729, $6851,~~416~~724 and $~~125~~177,~~510~~234 for the three and ~~six~~nine months ended ~~June~~September 30, 2025 and 2024, respectively.

Patents

The Company capitalizes external costs, such as filing fees and associated attorney fees, incurred to obtain issued patents. The Company’s intangible assets consist of capitalized costs for unissued patents and issued patents. Issued patents are carried at cost less accumulated amortization. Successful patent efforts are amortized over the life of the patent, and unsuccessful efforts are expensed. The issued patents are being amortized over a useful life of 20 years. Amortization of the patent costs commences upon patent issuance.

Net unissued and issued patents were $1,~~153~~176,~~709~~093 and $~~839~~828,~~560~~678 as of ~~June~~September 30, 2025, respectively; and $1,110,815 and $862,014 as of December 31, 2024, respectively. The Company assesses the carrying value of its intangible assets for impairment each year and when indicators exist that there could be an impairment. Based on its assessments, the Company did not incur any impairment charges for the three and ~~six~~nine months ended ~~June~~September 30, 2025 and 2024, respectively.

Amortization expense of patents was $20,882, $4364,~~248~~130, $3449,~~495~~778 and $71121,~~793~~571 for the three and ~~six~~nine months ended ~~June~~September 30, 2025 and 2024, respectively. Future amortization expense for the ~~patents~~ patents over the next five years is anticipated to be approximately $83,528 per year.

Leases

The Company determines whether an arrangement is a lease at inception. For leases where the Company is the lessee, right-of-use assets are recognized as the lease liability, adjusted for lease incentives received and prepayments made. Lease liabilities are recognized based on the present value of remaining lease payments over the lease term. When the Company’s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Leases with an initial lease term of 12 months or less are not recorded on the condensed consolidated and combined balance sheet.

The Company has elected the short-term lease practical expedient under ASC 842, applying it consistently to all leases with an initial term of 12 months or less, which are excluded from the condensed consolidated and combined balance sheet. Lease expense for these leases is recognized on a straight-line basis over the lease term. The Company had no right-of-use assets or lease liabilities recorded on its condensed consolidated and combined balance sheets as of ~~June~~September 30, 2025 and 2024, respectively.

1112

Foreign Operations

The functional currency of Solidion’s Taiwan subsidiary is the New Taiwan Dollar. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 830, Foreign Currency Matters, the financial statements of the Company’s Taiwan subsidiary are translated to U.S. dollars using the exchange rates at the balance sheet dates for assets and liabilities, the historical exchange rate for stockholders’ equity accounts and a weighted average exchange rate for revenue, expenses and gains or losses. Foreign currency translation adjustments are accumulated in a separate component of stockholders’ deficit until the foreign business is sold or substantially liquidated. Foreign currency translation adjustments for the periods presented in these financial statements were not material.

During prior reporting periods, the Company’s research and development facility in Taiwan — , operating as an extension of the Dayton, Ohio R&D team and focused on silicon anode technology ~~advancement — represented $5,400 and $18,290 of total assets and $20,000 and $22,053 of total liabilities as of~~ ~~June 30, 2025 and December 31, 2024, respectively~~ advancement.

During the three months ended March 31, 2025, the Company ceased research and development operations at its Taiwan location. The results of operations for this location were immaterial to the Company’s condensed consolidated and combined financial statements for all periods presented. No material exit or disposal costs were incurred in connection with the shutdown.

Revenue Recognition

Revenue is recognized when a performance obligation has been satisfied by transferring control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products. Revenues are recognized at a point in time when control transfers to customers, which is generally determined when title, ownership and risk of loss pass to the customer.

Research and Development

All research and development costs are expensed as incurred.

Selling, General and Administrative Expenses

Selling, general and administrative expenses represent costs incurred by the Company in managing the business, including salary, benefits, stock-based compensation, sales, insurance, professional fees and other operating costs associated with the Company’s non-research and development activities.

Stock-Based Compensation

The Company has an incentive equity plan, (“2023 Equity Incentive Plan”). Under the terms of the plan, Solidion’s employees, consultants and directors, and employees and consultants of its affiliates, may be eligible to receive awards in the form of incentive stock options (“ISOs”) to employees and for the grant of non-statutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors and consultants.

The number of shares of common stock initially reserved for issuance under the incentive plan is 190,000. Shares subject to stock awards granted under the incentive plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the incentive plan. The incentive plan also includes an evergreen provision that provides for an automatic annual increase to the number of shares of common stock available for issuance under the incentive plan on the first day of each fiscal year beginning with the 2024 fiscal year, equal to the least of (i) 190,000 shares of common stock, (ii) 5% of the total number of shares of common stock outstanding as of the last day of our immediately preceding fiscal year, or (iii) such lesser amount determined by the plan administrator.

1213

The Company measures stock options and restricted stock unit awards granted to employees, non-employees, and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards, over the requisite service period, which is generally the vesting period of the respective award. Options granted under the 2023 Equity Incentive Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. The plan administrator determines the term of stock options granted under the incentive plan, up to a maximum of ten years. Forfeitures are accounted for as they occur.

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Stock-based compensation expense for restricted stock units is measured based on the grant-date fair value of the awards and recognized as expense over the requisite service period, which is generally the vesting period. The Company has elected to use the accelerated attribution method, under which each vesting tranche of an award is treated as a separate award and expensed over its respective vesting period. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated at the grant date and adjusted prospectively, if necessary.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company lacks a sufficient history of company-specific historical and implied volatility information for its common stock. The Company therefore estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price.

The expected term of all of the Company’s stock options has been determined utilizing the “simplified” method. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.

Net Income (Loss) per Common Stock

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period.

The calculation of diluted income (loss) per share of common stock does not include potentially dilutive common stock equivalents if their inclusion would be anti-dilutive as of ~~June~~ September 30, 2025 and 2024. As such, net loss per common stock is the same for basic and diluted loss per share for the ~~six~~three and nine months ended September ~~June~~ 30, 2024 and for the three months ended September 30, 2025.

13The following table presents potentially dilutive common stock equivalents that have been excluded from the calculation of dilutive loss per share for the three and nine months ended September 30, 2024 as their inclusion would be anti-dilutive:

The following table presents potentially dilutive common stock equivalents that have been excluded from the calculation of dilutive loss per share for the six months ended June 30, 2024 as their inclusion would be anti-dilutive:

	September 30, 2024
Holdback Shares		4,000
Warrants - Public		123,500
Warrants - Private		108,100
Warrants - Series A		433,514
Warrants - Series B		7,711
Warrants - Series C		488,699
Warrants - Series D		244,349
Stock-based compensation - equity awards		6,000
Arbor Lake Strategic Cooperation Consulting Agreement		40,000
HBC Earnout Shares		450,000
Total common stock equivalents excluded from dilutive loss per share		1,905,873

	June 30, 2024
Holdback Shares		4,000
Warrants - Public		123,500
Warrants - Private		108,100
Warrants - Series A		442,834
Warrants - Series B		110,993
Stock-based compensation - equity awards		6,000
Forward Purchase Agreement - Additional Shares		160,771
HBC Earnout Shares		450,000
Total common stock equivalents excluded from dilutive loss per share		1,406,198

The following table presents potentially dilutive common stock equivalents that have been ~~included~~excluded infrom the calculation of dilutive ~~income~~loss per share for the three months ended ~~June~~ September 30, ~~2024,~~ 2025 as their inclusion would be anti-dilutive.:

	June 30, 2024
	September 30, 2025
Warrants - Series B		110,993
Holdback Shares		4,000
Stock-based compensation - equity awards		6,000
Warrants - Public		123,500
Convertible notes		67,925
Warrants - Private		108,100
Total common stock equivalents included in dilutive income per share		184,918
Warrants - Series A		652,857
Warrants - Series C		2,461,538
Warrants - Series D		244,349
Stock-based compensation - equity awards		38,000
Stock-based compensation - warrants		12,000
Arbor Lake Strategic Cooperation Consulting Agreement		40,000
HBC Earnout Shares		450,000
Total common stock equivalents excluded from dilutive loss per share		4,134,344

The following table presents potentially dilutive common stock equivalents that have been included in the calculation of dilutive income per share for the ~~three~~nine months ended ~~June~~September 30, 2025, as their inclusion would be dilutive.

	June 30, 2025
	September 30, 2025
Warrants - Series A		42414,~~975~~909
Warrants - Series C		~~119~~1,~~472~~519,476
Stock-based compensation - equity awards		3237,~~136~~417
Total common stock equivalents included in dilutive income per share		~~194~~1,~~583~~971,802

The following table presents potentially dilutive common stock equivalents that have been included in the calculation of dilutive income per share for the six months ended June 30, 2025, as their inclusion would be dilutive.

	June 30, 2025
Warrants - Series A		109,007
Warrants - Series C		340,620
Stock-based compensation - equity awards		32,136
Total common stock equivalents included in dilutive income per share		481,763

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial institutions, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). See Note 13.

Equity-Linked Instruments

The Company evaluates all equity-linked contracts, including warrants and the Forward Purchase Agreement (“FPA”), to determine classification as either equity or liability in accordance with FASB ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and FASB ASC 815, Derivatives and Hedging (“ASC 815”). This assessment considers whether the instruments meet the fixed-for-fixed equity classification criteria and whether any provisions require liability treatment, including potential “net cash settlement” outside of the Company’s control. Instruments that qualify for equity classification are recorded as a component of additional paid-in capital, while those requiring liability classification are measured at fair value, with subsequent changes recorded in earnings. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the FPA and warrants are outstanding.

1415

Warrants

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The Company accounts for the outstanding public warrants and private placement warrants (“Private Warrants”) issued in connection with Nubia’s initial public offering in 2022 as equity-classified instruments under ASC 815-40 since they qualify as being indexed to the company’s own stock for equity classification criteria and do not contain provisions that would require liability classification.

The Company accounts for the outstanding Series A, Series B, Series C, and Series D warrants issued in connection with the March and August 2024 private placement financings (the “PIPE Warrants”) as liability-classified instruments because certain settlement adjustments prevent them from meeting the fixed-for-fixed equity classification criteria under ASC 815-40. The Company utilizes a Monte Carlo simulation model to determine the fair value of the PIPE Warrants. The resulting fair value is recorded as a derivative liability on the condensed consolidated and combined balance sheets, and with changes in the fair value of the PIPE Warrants recorded as a non-cash other income (expense) within change in fair value of derivative liabilities account on the Company’s condensed consolidated and combined statements of operations.

Forward Purchase Agreement

The Company accounts for the FPA as either equity-classified or liability-classified instruments based on an assessment of the FPA specific terms and applicable authoritative guidance in ASC 480, and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the FPA is a freestanding financial instrument pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the FPA meets all of the requirements for equity classification under ASC 815, including whether the FPA is indexed to the Company’s own common shares and whether the FPA holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of FPA issuance and as of each subsequent quarterly period end date while the FPA is outstanding.

For issued or modified FPA that meets all of the criteria for equity classification, the FPA is required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified FPA that does not meet all of the criteria for equity classification, the FPA is required to be recorded at fair value on the date of issuance and revalued at each balance sheet date thereafter. The Company accounts for the FPA as a liability-classified instrument due to the settlement provisions. The Company utilizes a Monte Carlo simulation model to determine the fair value of the FPA. The resulting fair value is recorded as a derivative liability on the condensed consolidated and combined balance sheets. The Company records changes in the fair value of the FPA as a non-cash other income (expense) within change in fair value of derivative liabilities account on the Company’s condensed consolidated and combined statements of operations.

Other Current Assets

The composition of other current assets was:

	June 30, 2025		December 31, 2024
	September 30, 2025		December 31, 2024
Directors & officers insurance		~~431~~253,~~608~~887		-
Total other assets		~~431~~253,~~608~~887		-

Reverse Stock Split

On May 12, 2025, the Company effected a 1-for-50 reverse stock split of its common stock. As a result, each 50 shares of common stock issued and outstanding immediately prior to the reverse split were converted into one share of common stock. Additionally, this transaction resulted in a reclassification of $13,311 from common stock to additional paid-in capital during the period ended March 31, 2025. The reverse stock split did not change the total number of authorized shares or the par value of the common stock. During the three month period ended June 30, 2025, the Company paid cash of approximately $460 to shareholders in lieu of issuing fractional shares.

In accordance with SEC Staff Accounting Bulletin Topic 4C, all share and per-share amounts in the accompanying condensed consolidated financial statements and notes have been retroactively adjusted to reflect the reverse stock split for all periods presented.

Recently Adopted Accounting Standards

In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” to enhance disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. The standard did not change the definition of a segment, the method for determining segments or the criteria for aggregating operating segments into reportable segments. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods presented in the financial statements. The Company adopted the amendment effective January 1, 2024 for annual reporting purposes. The adoption did not have a material impact to the Company’s financial statements or disclosures.

1516

Recently Issued Accounting Standards

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which requires disclosures of incremental income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. ASU 2023-09 is effective for the fiscal year beginning after December 15, 2024. Early adoption is permitted. The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.

In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures by providing more detailed information about the types of expenses in commonly presented expense captions. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures.

NOTE 4 — RECAPITALIZATION

As discussed in Note 1, the Merger was accounted for as a common control transaction with respect to HBC which is akin to a reverse recapitalization.

Transaction Proceeds

Upon the Closing, the Company received net proceeds of $17,555 after deducting transaction costs. The following table reconciles the elements of the Merger to the condensed consolidated and combined statements of cash flows and the condensed consolidated and combined statements of changes in stockholders’ equity (deficit) for the period ended March 31, 2024:

Cash received from NUBI Trust	25,160,047
Less: discount payment related to Non Redemption Agreement	(13,937,997	)
Less: reimbursement for consideration shares related to the FPA	(2,193,800	)
Less: reimbursement for Recycled Shares related to the FPA	(80,241	)
Less: transaction expenses paid in connection with the Merger	(8,948,009	)
Net cash received from NUBI Trust	-
Add: cash from NUBI operating account	17,555
Add: prepaid expenses	165,407
Less: derivative liabilities	(20,889,950	)
Less: other liabilities	(4,086,172	)
Reverse recapitalization, net	(24,793,160	)

The number of shares of common stock issued immediately following the consummation of the Merger were:

Nubia common stock, outstanding prior to the closing of the Merger			120,095
Shares issued to Nubia convertible noteholders			119,247
Predecessor HBC Shares			1,396,000
Common stock immediately after the closing of the Merger			1,635,342

The number of Predecessor HBC shares was determined as follows:

		Predecessor HBC Shares				Shares issued to shareholders of Predecessor HBC
Common stock			1,000				1,396,000

1617

IPO warrants

In connection with Nubia’s initial public offering in 2022, 123,500 public warrants and 108,100 Private Warrants were issued, all of which remain outstanding and became warrants for the Common stock in the Company. The Company evaluated the IPO warrants and determined that it is a freestanding equity-linked contract within the scope of ASC 815-40. Based on this guidance, the Company concluded that the IPO warrants qualify for equity classification.

HBC Holdback Shares

The Company and G3 included a provision in the Merger Agreement that adjusts the aggregate share consideration to be paid to the shareholders of HBC if the G3 Tax Lien is not released prior to closing. Specifically, 4,000 shares of Solidion common stock, issuable to the HBC shareholders as part of the Merger Consideration at or following closing, will depend on whether the G3 Tax Lien has been settled by G3 prior to closing. See Note 6 for further discussion regarding Holdback Shares related to the G3 Tax Lien. As of the Merger closing and the three months ended ~~June~~September 30, 2025, the G3 Tax Lien remained unresolved by G3, and the 4,000 holdback shares had not been issued as of ~~June~~September 30, 2025.

HBC Earnout Arrangement

As noted in Note 1, in connection with the Merger, HBC shareholders are entitled to up to 450,000 shares if certain post merger per share market prices are achieved. The Company evaluated the Earnout Arrangement and determined that it is a freestanding equity-linked contract within the scope of ASC 815-40. Based on this guidance, the Company concluded that the Earnout Arrangement qualifies for equity classification. As the merger has been accounted for as a reverse recapitalization, the fair value of the Earnout Arrangement has been accounted for as an equity transaction as of the Closing Date of the Merger. The Company utilized a Monte Carlo simulation analysis to determine the fair value of the Earnout Arrangement at the date of the merger, which included the following assumptions: stock price of $4226.5350, risk free rate of 3.98%, volatility of 85%, dividends yield of 0% and duration of 4 years.

As of ~~June~~September 30, 2025, none of the Earnout ~~Shares~~ Shares had been earned by G3.

On October 9, 2025, the Company issued 450,000 shares of its common stock to G3 pursuant to the earnout provisions of the Merger Agreement. These shares represent the full amount of the Earnout Shares described above. See Note 1 for more details.

NOTE 5 — RELATED PARTIES

Capital Contributions from Global Graphene Group (“G3”)

G3, a significant shareholder of the Company, infused capital resources into the business to cover operating expenses incurred prior to the close of the merger. The capital contributions from G3 included allocations for payroll, rent and facility costs, and professional services. The total capital contributions from G3 amounted to $0 and $487,273 ~~during~~ during the three and ~~six~~nine months ended ~~March~~September 3130, 2024, respectively. No capital contributions were made during the corresponding periods in 2025.

Other Receivable

During the three months ended March 31, 2024, the Company advanced $302,500 to G3 for transaction costs incurred during the Merger. The outstanding balance of other receivables amounted to $302,500 as of ~~June~~September 30, 2025 and December 31, 2024.

1718

Shared Services Agreement

Effective February 2, 2024, the Company entered into a shared services agreement (the “SSA”) with G3, under which G3 agreed to provide certain services, including employees, office space and use of equipment, and the Company agreed to pay for such services on a monthly basis. The SSA is subject to typical conditions and may be terminated by either party upon written notice. The management and board continues to monitor the SSA and all other related party transactions to uphold transparency and protect shareholder interests. Expenses incurred related to the SSA services were $6080,~~692~~973, $~~123~~204,~~280~~253, $4539,~~269~~ 000 and $76115,521, respectively for the three and ~~six~~nine months ended ~~June~~September 30, 2025 and 2024. Expenses incurred related to the SSA employees were $8153,~~311~~831, $~~278~~331,~~101~~932, $~~220~~83,~~516~~902 and $~~310~~394,~~435~~336, respectively for the three and ~~six~~nine months ended ~~June~~September 30, 2025 and 2024. There were $49156,~~189~~717 and $10,000 in amounts outstanding as of ~~June~~September 30, 2025 and December 31, 2024, respectively.

Due to Related Party

During the merger closing process, G3 incurred certain transaction expenses that were due to be reimbursed by the Company after the Closing Date, as per the Business Combination Agreement. These expenses included legal, advisory and audit fees directly associated with facilitating the merger. The total amount due to G3 was $879,985 as of the Closing Date. During the year ended December 31, 2024, the Company repaid the $879,985 due to G3.

Additionally, at the time of the merger close, the Company had an outstanding payable related to the monthly administrative services support fees due to Mach FM Corp, an affiliate of Mach FM Acquisitions LLC, the sponsor of Nubia. This fee covered office space, utilities, and secretarial and administrative support provided by Mach FM to support Nubia’s operating activities. The outstanding balance payable to Mach FM amounted to $88,979 as of the Closing Date.

As of ~~June~~September 30, 2025 and December 31, 2024, ~~amounts~~ amounts outstanding to G3 were $0, and amounts outstanding to Mach FM Corp were $87,873.

Contingent Consideration

At Closing, the G3 Tax Lien has not been settled by G3 and as of ~~June~~September 30, 2025, the 4,000 Holdback Shares have not been issued. The contingent consideration represents a potential ~~obligation~~ obligation that would become released only upon G3 settling its G3 Tax Lien. See Note 4 further discussion regarding Holdback Shares related to the G3 Tax Lien.

As of the Closing Date, the Company recorded a fair value of $906,000 for the 4,000 Holdback Shares, which was accounted for as an equity transaction.

NOTE 6 — COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company may be involved in lawsuits, claims or legal proceedings that arise in the ordinary course of business, including proceedings related to the Company’s obligation to register shares for public offering. The Company accrue a contingent liability when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Management believes that there are no claims against us for which the outcome is expected to have a material effect on our financial position, results of operations or cash flows.

1819

G3 Tax Lien

The Internal Revenue Service has placed a federal tax lien on all the property and rights to property belonging to G3 which would include any proceeds from sale of property assets included in the financial statements of the Company. The lien relates to unpaid federal income taxes for 2017. Inclusive of interest, the balance owed is approximately $2,~~080~~120,000 as of ~~June~~September 30, 2025.

As disclosed in Note 3, the Company and G3 included a provision in the Merger Agreement that adjusts the aggregate share consideration to be paid to the shareholders of HBC if the G3 Tax Lien is not released prior to closing. Specifically, 4,000 shares of Solidion common stock, issuable to the HBC shareholders as part of the Merger Consideration at or following closing, will depend on whether the G3 Tax Lien has been settled by G3 prior to closing. As of the Merger closing and through ~~June~~September 30, 2025, the G3 Tax Lien remained unsettled by G3 and as of ~~June~~September 30, 2025, the 4,000 ~~holdback~~ holdback shares have not been issued.

The G3 Tax Lien represents a potential obligation that would become payable only upon the sale of the building. As the timing and likelihood of such a sale are uncertain and there are no immediate plans to sell, the Company has not recorded a liability on the balance sheet for this contingent obligation. Should the Company decide to sell the building in the future, this lien may need to be settled from the proceeds of the sale, which could impact the net cash inflow from such a transaction. The Company will continue to monitor the situation and will recognize a liability in the financial statements if and when it becomes probable that the building will be sold and the lien will need to be satisfied.

Registration Rights Agreement

Pursuant to the Registration Rights Agreement, dated August 30, 2024 (the “Agreement”), between the Company and the purchasers of privately placed securities (the “Purchasers”), the Company was obligated, among other things, to file a registration statement to register the resale of such securities and to have the Securities and Exchange Commission declare the registration statement effective by certain deadlines specified in the Agreement. As of ~~June~~September 30, 2025, the Company had not met these deadlines. As a result, the Company recorded an expense within Selling, General, ~~and~~ and Administrative Expenses on its consolidated and combined statements of operations of $0 and $160,000 during the three and ~~six~~ nine months ended ~~June~~September 30, 2025. The total liquidated damages are limited to approximately $400,000 plus interest calculated in accordance with the Agreement.

On October 8, 2025, (the “Effective Date”), Madison Bond LLC and Bayside Project LLC (together, the “New Holders”) purchased all of the outstanding Series C and Series D Warrants previously issued by the Company pursuant to the August Subscription Agreement. Immediately thereafter, the Company exercised its rights under the August Subscription Agreement to convert all remaining unexercised portions of the Series C and Series D Warrants into shares of common stock at a ratio of one share per warrant. On October 24, 2025, the New Holders received 3,447,957 shares of the Company’s common stock (the “Conversion Shares”), and all outstanding Series C and Series D Warrants were cancelled.

NOTE 7 — STOCKHOLDERS’ EQUITY (DEFICIT)

Preferred Stock

The Company is authorized to issue 2,000,000 shares of preferred stock with a par value of $0.0001 per share. As of ~~June~~September 30, 2025 and December 31, 2024, there were no shares of preferred stock issued or outstanding.

1920

Common Stock

The Company is authorized to issue 300,000,000 shares of common stock with a par value of $0.0001 per share. Holders of common stock are entitled to one vote for each share. As of ~~June~~September 30, 2025 and December 31, 2024, respectively, there were 2,~~716~~874,~~794~~326 and 2,633,956 shares of common stock issued and outstanding, respectively.

Equity Financing

On March 13, 2024, Solidion entered into a private placement transaction (the “March Private Placement”), pursuant to a Securities Purchase Agreement (the “March Subscription Agreement”) with certain institutional investors (the “Purchasers”) for aggregate gross proceeds of $3,850,000. The issuance costs associated with the March Private Placement, including fees to the placement agent and other expenses, totaled $522,867, of which $262,064 was allocated to the issuance of March Private Placement common stock and $260,803 was allocated to the issuance of series A and B warrants. The March Private Placement closed on March 15, 2024.

As part of the March Private Placement, the Company issued an aggregate of 102,667 units and pre-funded units (collectively, the “Units”) at a purchase price of $37.50 per unit (less $0.0001 per pre-funded unit). Each Unit consists of (i) one share of Solidion Common Stock, (ii) two Series A warrants (“Series A Warrants”) each to purchase one share of Common Stock, and (iii) one Series B warrant (“Series B Warrants”) to purchase such number of shares of Common Stock as determined on the reset date, and in accordance with the terms therein.

On August 30, 2024, the Company entered into a private placement transaction (the “August Private Placement”), pursuant to a Securities Purchase Agreement (the “August Subscription Agreement”) with certain institutional investors (the “Purchasers”) for aggregate gross proceeds of $4,000,000. The issuance costs associated with the August Private Placement, including fees to the placement agent and other expenses, totaled $380,001, of which $157,435 was allocated to the issuance of August Private Placement common stock and $222,566 was allocated to the issuance of Series C and D warrants. The August Private Placement closed on September 5, 2024. The Company used the net proceeds from the August Private Placement for working capital and general corporate purposes.

As part of the August Private Placement, the Company issued an aggregate of 244,349 units and pre-funded units (collectively, the “Units”) at a purchase price of $16.37 per unit. Each Unit consists of (i) one share of common stock, par value $0.0001 per share of the Company (the “Common Stock”) (or one pre-funded warrant to purchase one share of Common Stock (the “Pre-Funded Warrant”)), (ii) two Series C warrants each to purchase one share of Common Stock (the “Series C Warrant”) and (iii) one Series D warrant to purchase such number of shares of Common Stock as determined on the Reset Date (as defined below), and in accordance with the terms therein (the “Series D Warrant” and together with the Pre-Funded Warrant and the Series C Warrant, the “Warrants”).

The Company accounts for the outstanding PIPE Warrants as liability-classified instruments because certain settlement adjustments prevent them from meeting the fixed-for-fixed equity classification criteria under ASC 815-40. The Company utilizes a Monte Carlo simulation model to determine the fair value of the PIPE Warrants. The resulting fair value is recorded as a Derivative liability on the condensed consolidated and combined balance sheets, and records changes in the fair value of the PIPE Warrants as a non-cash other income (expense) within Change in fair value of derivatives account on the Company’s condensed consolidated and combined statements of operations.

2021

NOTE 8 — WARRANTS

IPO Warrants – Public Warrants

In connection with Nubia’s initial public offering in 2022, 123,500 public warrants were issued, entitling holders to purchase one share of common stock at an exercise price of $575.00 per share, subject to adjustment. Only whole warrants may be exercised. The warrants expire five years after the completion of the Company’s initial business combination, February 2, 2029.

The Company is not obligated to issue shares upon warrant exercise unless a registration statement covering the underlying shares is effective. If a registration statement is not effective, holders may exercise warrants on a cashless basis under certain conditions. The Company may redeem the warrants at $0.50 per warrant, with at least 30 days’ prior notice, if the common stock trades at or above $900.00 per share for 20 trading days within a 30-day period after the warrants become exercisable. Adjustments to the number of shares issuable upon exercise and the exercise price may occur in the event of stock splits, dividends, reorganizations, or similar events. Warrants do not provide voting rights or shareholder privileges until exercised. No fractional shares will be issued upon exercise.

The Company evaluated the public warrants and determined that it is a freestanding equity-linked contract within the scope of ASC 815-40. Based on this guidance, the Company concluded that the IPO warrants qualify for equity classification.

IPO Warrants – Private Warrants

In connection with Nubia’s initial public offering in 2022, 108,100 Private Warrants were issued.

Except as described below, the Private Warrants have terms and provisions that are identical to those of the public warrants, including as to exercise price, exercisability and exercise period. The Private Warrants will be exercisable on a cashless basis and will not be redeemable by us so long as they are held by the holders of the private warrants or their permitted transferees. The holders of the Private Warrants or their permitted transferees have the option to exercise the private warrants on a cashless basis. If the Private Warrants are held by holders other than the holders of the Private Warrants and their permitted transferees, the Private warrants will be redeemable by us and exercisable by the holders on the same basis as the warrants included in the units being sold in the Company’s initial public offering.

If exercised on a cashless basis, holders will receive shares of common stock based on the difference between the warrant exercise price and the fair market value of the stock. Fair market value is determined as the average last sale price of the common stock over the 10 trading days ending on the third trading day before the exercise notice date. The reason that The Company have agreed that these warrants will be exercisable on a cashless basis so long as they are held by the holders of the Private Warrants and their permitted transferees is because it is not known at this time whether they will be affiliated with us following an initial business combination. If they remain affiliated with us, their ability to sell the Company’s securities in the open market will be significantly limited. The Company has policies in place that prohibit insiders from selling the Company’s securities except during specific periods of time. Even during such periods of time when insiders will be permitted to sell the Company’s securities, an insider cannot trade in the Company’s securities if he or she is in possession of material non-public information. Accordingly, unlike public stockholders who typically could sell the shares of common stock issuable upon exercise of the warrants freely in the open market, the insiders could be significantly restricted from doing so. As a result, The Company believes that allowing the holders to exercise such warrants on a cashless basis is appropriate.

In addition, holders of the Company’s Private Warrants are entitled to certain registration rights.

The Company evaluated the Private Warrants and determined that it is a freestanding equity-linked contract within the scope of ASC 815-40. Based on this guidance, the Company concluded that the Private Warrants qualify for equity classification.

Series A and Series B Warrants

The Series A and Series B Warrants issued in conjunction with the March Private Placement were determined to be liability classified in accordance with ASC 815 and have been recognized at fair value upon issuance, with remeasurement in each subsequent period. As such, on the date of issuance the Company allocated the proceeds between the common stock, Series A Warrants and Series B Warrants first to the fair value of the Series A Warrants and Series B Warrants, which were recorded as a liability.

The Company used a Monte Carlo analysis to determine the fair value of the warrants at the date of issuance on March 15, 2024 and as of the reporting date. The total fair value of the Series A Warrants and Series B Warrants measured at issuance was $12,656,550 and $82,450, respectively, which exceeded the total gross proceeds from the March Private Placement of $3,850,000. As the fair value of the derivative liability exceeded the proceeds on the day of issuance, the difference was recorded as a loss from issuance of stock and warrants of $17,820,998.

2122

On May 12, 2025, the Company effected a 1-for-50 reverse stock split of its common stock. Following the reverse split, the 5-day reset period ended on May 19, 2025, with the lowest 5-day VWAP on May 14, 2025, being $3.0951. Consequently, the reset price was established at $3.0951, and the Series A Warrants held by investors were reset to 810,389 shares. The Series B Warrants were not subject to a post-split reset because no Series B Warrants were outstanding at the time the reverse stock split became effective. The fair value of the Series A and Series B Warrants as of ~~June~~September 30, 2025, was $~~527~~2,~~100~~715,900 and $0, respectively. The Company recorded non-cash ~~gains~~gain (loss) from changes in the fair value of derivative liabilities related to the Series A and Series B Warrants of $~~162~~71,~~400~~850 and $42,~~428~~239,~~200~~400 for the three and ~~six~~nine months ended ~~June~~September 30, 2025, respectively, compared to $95,~~141~~383,~~900~~585 and $~~710~~6,~~050~~093,635 for the three and ~~six~~nine months ended ~~June~~September 30, 2024. As of ~~June~~September 30, 2025, ~~289~~investors had exercised 447,~~613~~145 Series A Warrants and 114,992 Series B Warrants ~~were exercised~~, resulting in the issuance of ~~404~~ 562,~~605~~137 common shares. As of ~~June~~September 30, 2025, ~~153~~652,~~221~~857 Series A Warrants and no Series B Warrants remained outstanding.

Series C and Series D Warrants

The Series C and Series D Warrants issued in conjunction with the August Private Placement were determined to be liability classified in accordance with ASC 815 and have been recognized at fair value upon issuance, with remeasurement in each subsequent period. As such, on the date of issuance the Company allocated the proceeds between the common stock, Series C Warrants and Series D Warrants first to the fair value of the Series C Warrants and Series D Warrants, which were recorded as a liability.

The Company used a Monte Carlo analysis to determine the fair value of the warrants at the date of issuance on August 30, 2024 and as of the reporting date. The total fair value of the Series C Warrants and Series D Warrants measured at issuance was $8,114,650 and $1,540,150, respectively, which exceeded the total gross proceeds from the August Private Placement of $4,000,000. As the fair value of the derivative liability exceeded the proceeds on the day of issuance, the difference was recorded as a loss from issuance of stock and warrants of $9,654,799.

On May 12, 2025, the Company effected a 1-for-50 reverse stock split of its common stock. Following the reverse split, the 5-day reset period ended on May 19, 2025, with the lowest 5-day VWAP on May 14, 2025, being the price floor of $3.25. Consequently, the reset price was established at $3.25, and the Series C Warrants held by investors were reset to 2,461,538 shares. The Series D warrants were not subject to a post-split reset based on the terms of the agreement. The fair value of the Series C Warrants and Series D Warrants as of ~~June~~ September 30, 2025 was $78,~~037~~684,~~100~~300 and $23,~~493~~022,~~900~~200, respectively, resulting in a non-cash gain (loss) of $1(2,~~500~~175,~~300~~500) and $42,~~382~~206,~~250~~750 during the three and ~~six~~nine months ended ~~June~~September 30, 2025, respectively, compared to a gain of $435,550 for the three and nine months ended September 30, 2024. There were no Series C Warrants and Series D Warrants exercised as of ~~June~~September 30, 2025.

On October 8, 2025, Madison Bond LLC and Bayside Project LLC (together, the “New Holders”) purchased all of the outstanding Series C and Series D Warrants previously issued by the Company pursuant to the August Subscription Agreement. Immediately thereafter, the Company exercised its rights under the August Subscription Agreement to convert all remaining unexercised portions of the Series C and Series D Warrants into shares of common stock at a ratio of one share per warrant. On October 24, 2025, the New Holders received 3,447,957 shares of the Company’s common stock (the “Conversion Shares”), and all outstanding Series C and Series D Warrants were cancelled.

NOTE 9 — FORWARD PURCHASE AGREEMENT, NON REDEMPTION AGREEMENT AND PRIVATE PLACEMENT FINANCING

Forward Purchase Agreement

On December 13, 2023, Nubia entered into the FPA with Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Strategic Capital, LLC (collectively, the “Seller” or “Forward Purchase Investors”). For purposes of the FPA, Nubia is referred to as the “Counterparty” prior to the consummation of the Merger, while Solidion Technology, Inc. (“Pubco”) is referred to as the “Counterparty” after the consummation of the Merger. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to such terms in the FPA previously filed with the SEC.

Pursuant to the terms of the Forward Purchase Agreement, Seller intends, but is not obligated, to, concurrently with the Closing pursuant to Seller’s FPA Funding Amount PIPE Subscription Agreement, purchase up to 9.9% of the total Class A ordinary shares, par value $0.0001 per share (“Additional Shares”) outstanding following the closing of the Merger, as calculated by Seller (the “Purchased Amount”), less the number of NUBI Shares purchased by Seller separately from third parties through a broker in the open market (“Recycled Shares”). Seller will not be required to purchase an amount of NUBI Shares such that, following such purchase, that Seller’s ownership would exceed 9.9% of the total NUBI Shares outstanding immediately after giving effect to such purchase, unless Seller, at its sole discretion, waives such 9.9% ownership limitation. The Number of Shares subject to the Forward Purchase Agreement is subject to reduction following a termination of the Forward Purchase Agreement with respect to such shares as described under “Optional Early Termination” in the Forward Purchase Agreement.

The FPA provides for a prepayment shortfall equal to 0.50% of the product of Recycled Shares and the Initial Price. The Seller may conduct Shortfall Sales at its discretion to recover this shortfall without triggering early termination obligations. The Prepayment Amount payable to the Seller is calculated based on the number of shares purchased and the redemption price, less any prepayment shortfall, and is funded from the Counterparty’s Trust Account. Additionally, up to 4,000 shares may be purchased at the Initial Price.

Following the Closing, the reset price (the “Reset Price”) was initially the Initial Price. The Reset Price will be subject to reset on a bi-weekly basis commencing the first week following the thirtieth day after the closing of the Merger to be the lowest of (a) the then current Reset Price, (b) the Initial Price and (c) the VWAP Price of the Shares of the prior two weeks; provided the Reset Price shall be subject to reduction upon a Dilutive Offering Reset immediately upon the occurrence of such Dilutive Offering. The Seller also retains the right to terminate part or all of the transaction through Optional Early Termination (OET) by providing notice, with corresponding payment obligations based on the Reset Price.

2223

The Valuation Date for settlement occurs at the earlier of three years post-Merger, specified adverse events (e.g., delisting or registration failure), or at the Seller’s discretion. Upon settlement, adjustments may be made in cash or shares, depending on the circumstances.

The Seller has waived redemption rights for Recycled Shares, which may impact the overall redemption levels and market perception of the Merger. The FPA complies with tender offer regulations, including Rule 14e-5 under the Securities Exchange Act of 1934.

On February 2, 2024, upon consummation of the Merger, NUBI made a payment to each Forward Purchase Investor in respect of their respective Recycled Shares. This payment totaled 147 shares and included a cash payment of $80,241 released from the trust account. The payment was calculated as an amount equal to (a) the number of Recycled Shares multiplied by the redemption price per share (the “Initial Price”) as defined in Section 9.2(b) of NUBI’s Certificate of Incorporation, effective as of March 10, 2023, as amended from time to time (the “Certificate of Incorporation”), less (b) the prepayment Shortfall. Additionally, on February 2, 2024, NUBI made a payment to Forward Purchase Investors of $2,193,800 from the trust account as reimbursement for the ~~147~~4,000 consideration shares.

On January 17, 2024, the Company received a Pricing Date Notice from the Forward Purchase Investors specifying 116,771 Additional Shares. On March 22, 2024, the Company received an amended Pricing Date Notice revising the total number of Additional Shares to 160,771. On June 11, 2024 the Company received an amended Pricing Date Notice revising the total number of Additional Shares to 190,860. On August 29, 2024, the Additional Shares were issued to the Forward Purchase Investors.

The Company accounts for the FPA as a liability-classified instrument due to the settlement provisions. The resulting fair value is recorded as a derivative liability on the consolidated balance sheets. The Company records changes in the fair value of the FPA as a non-cash other income (expense) within change in fair value of derivatives account on the Company’s consolidated and combined statements of operations.

The Company utilized a Monte Carlo simulation model to determine the fair value of the FPA, comprising Recycled Shares of 147 and Additional Shares of 190,860, totaling 191,007 shares (the “FPA Shares”) as of ~~June~~September 30, 2025 and December 31, 2024. The model estimated the total present value of the Company’s proceeds at $23,~~811~~ 777 and the total present value of the Company’s liability at $~~755~~889,~~425~~739, resulting in a net liability of approximately $~~752~~886,~~600~~000 as of September ~~June~~ 30, 2025. As a result, the Company recognized non-cash ~~gains~~gain (loss) from changes in the fair value of derivatives of $~~381~~(133,~~800~~ 400) and $5,~~651~~518,~~500~~100 for the three and ~~six~~nine months ended ~~June~~September 30, 2025, respectively, compared to $151,~~824~~413,~~800~~700 and $1617,~~074~~487,~~150~~850 for the three and ~~six~~nine months ended ~~June~~ September 30, 2024.

FPA amendment and resolution of lawsuit

On July 16, 2024, the Forward Purchase Investors brought a lawsuit against Solidion in Delaware Chancery Court seeking specific performance and monetary damages related to the FPA.

On August 29, 2024, the Company and the Seller entered into an amendment (the “Amendment”) to the FPA. The Amendment includes modifications to several terms, including:

●

Prepayment Shortfall: Expanded to allow the Company to request additional funds in increments of $500,000, subject to specified conditions.

●

Prepayment Shortfall Consideration: Seller may now sell Additional Shares and Recycled Shares at any price, without an Early Termination Obligation, until sale proceeds reach 120% of the Prepayment Shortfall.

●

Shortfall Sales: The Company agrees not to issue or sell additional shares or convertible securities without Seller’s consent until specific conditions are met.

●

Shortfall Variance: If a shortfall occurs, the Company must either pay the Shortfall Variance in cash or issue additional shares to the Seller.

●

Share Consideration: Seller is entitled to designate 57,000 common shares as (“Share Consideration”)

●

VWAP Trigger Event: Defined as occurring if the VWAP Price falls below $100.00 per share for 10 trading days within a 30-day period.

In addition, upon execution of the Amendment, the Seller agreed to temporarily forbear from exercising any rights under the Forward Purchase Agreement related to certain valuation events, including a Shortfall Variance Registration Failure, VWAP Trigger Event, or Registration Failure (collectively, “Valuation Date Events”), during the period from the Pricing Date through December 31, 2024 (the “Standstill Period”). After the Standstill Period, if any Valuation Date Events have occurred, the Seller’s rights under the agreement will be reinstated.

Additionally, the Company agreed to file a registration statement within 20 business days of the Amendment to register the resale of the Additional Shares and Share Consideration (collectively, the “Meteora Shares”). The Company will use commercially reasonable efforts to have the registration statement declared effective within 60 calendar days of the Amendment. No other shares may be registered before the Meteora Shares, though they may be registered concurrently in the same resale registration statement.

2324

Further, the Amendment restricts the Seller from selling more than 10% of the daily trading volume of the Company’s common stock until 30 days after the effectiveness of the resale registration statement, except on days when trading volume exceeds 140,000 shares.

Finally, concurrently with the execution of the Amendment, the Company and the Seller agreed to sign and cause to be filed a joint stipulation for dismissal with prejudice of the Action (as defined below) (the “Stipulation”). The Stipulation provides that the Company issue 247,860 Solidion common shares, consisting of the Additional shares of 190,860 and the Share Consideration of 57,000 shares to the Seller within five business days of the entry of the Stipulation. In consideration for the Stipulation, the Company agreed to pay Seller’s reasonable and documented attorney’s fees related to this Action in an amount up to $65,000. “Action” means (i) the Complaint for Specific Performance and Money Damages filed July 16, 2024 thereby initiating Case No. 2024-0752-LWW Meteora Capital Partners, LP v. Solidion Technology, Inc. in the Court of Chancery of the State of Delaware (the “Delaware Chancery Court”) and (ii) the Motion for Default Judgment filed by Seller related to such complaint on August 13, 2024. On September 9, 2024, the Company and the Seller filed the Stipulation in Delaware Chancery Court.

On August 29, 2024, the Company issued 247,860 Meteora Shares of its common stock to the Forward Purchase Investors.

The Company recorded an expense within Selling, General, and Administrative expenses on the Company’s condensed consolidated and combined statements of operations of $1,026,000 based on the stock price on the date of the amendment during the three months ended September 30, 2024 for the Consideration Shares of 57,000 Solidion common shares issued in connection with the forbearance and FPA amendment.

Non-Redemption Agreement

On December 13, 2023, NUBI entered into a non-redemption agreement (the “Non-Redemption Agreement”) with certain investors named therein (each, a “Backstop Investor”), each acting on behalf of certain funds, investors, entities or accounts that are managed, sponsored or advised by each such Backstop Investor or its affiliates. Pursuant to each Non-Redemption Agreement, each Backstop Investor agreed that, on or prior to Closing, it will beneficially own not greater than the lesser of (i) that number of Backstop Shares set forth in the Non-Redemption Agreement and (ii) the total number of NUBI Shares beneficially owned by Backstop Investor and its affiliates and any other persons whose beneficial ownership of NUBI Shares would be aggregated with those of Backstop Investor for purposes of Section 13(d) of the Securities Exchange Act of 1934 not exceeding 9.99% of the total number of issued and outstanding NUBI Shares, and shall not elect to redeem or otherwise tender or submit for redemption any of such Backstop Shares in connection with the second special meeting of NUBI stockholders to be held for the purpose of approving the Merger (the “Second Special Meeting”); provided, however, that in the event Backstop Investor has previously elected to redeem, tender or submit any Backstop Shares for redemption, Backstop Investor shall rescind or reverse such redemption request prior to Closing and NUBI shall accept such request(s) promptly once submitted by Backstop Investor.

On February 2, 2024, upon the consummation of the Merger, NUBI paid each Backstop Investor a cash discount payment from the proceeds remaining in trust account for their respective Backstop Shares as part of the Non-Redemption Agreement. The discount payment amount was calculated as the product of (x) the number of Backstop Shares and (y) the Redemption Price, less $200.00. The total number of Backstop Shares was 40,000, and the adjusted Redemption Price was $548.50 per share. In total, $13,937,998 was released from the trust account and paid to the Backstop Investors.

NOTE 10 — DEBT

Convertible Notes

At various dates during the first quarter of 2024, the Company issued convertible notes of $527,500 to meet our working capital requirements. At various dates during September and October 2024, the Company and three separate investors amended their respective convertible notes, resulting in a total of approximately an additional 2,707 common shares due upon conversion. As of December 31, 2024, there were five separate outstanding convertible notes, which are convertible into an aggregate of approximately 70,000 common shares. The outstanding balance on convertible notes was $527,500 as of December 31, 2024.

During the ~~six~~nine months ended ~~June~~September 30, 2025, holders converted an aggregate of $527,500 principal amount of convertible notes into 68,095 shares of common stock. As of ~~June~~September 30, 2025, convertible notes representing 1,600 shares remained outstanding and subject to conversion.

2425

Short-term Notes Payable

EF Hutton LLC

On February 1, 2024, the Company executed a Promissory Note with EF Hutton, totaling $2,200,000, to cover underwriters’ fees associated with the closure of the Company’s Merger with HBC. In the case of an event of default, this Note shall bear interest at a rate of 24% per annum until such event of default is cured. The principal amount of this Promissory Note is payable on designated dates, with $183,333 scheduled on the first business day of each month until the final payment on March 1, 2025. As of ~~June~~September 30, 2025, the Company was in default of the Promissory Note due to to non-payment of scheduled installments, and the Promissory Note is accruing interest at the default rate of 24% per annum. The Company is in the process of negotiating an amendment to the terms of the Promissory Note. The outstanding balance of the Promissory Note amounted to $1,283,335 as of ~~June~~September 30, 2025 and December 31, 2024. The accrued but unpaid interest on the Promissory Note totaled approximately $506,836 and 279,000 as of September 30, 2025 and December 31, 2024, respectively.

Benesch Friedlander Coplan & Aronoff LLP

On April 29, 2024, the Company executed a Promissory Note with Benesch Friedlander Coplan & Aronoff in the amount of $670,000. The interest rate is 7% per annum, to be paid as a lump sum at the maturity date of November 1, 2024.

On November 12, 2024, the Company amended the terms of its Promissory Note with Benesch Friedlander Coplan & Aronoff. The amended terms include an updated principal balance of $694,061, which includes unpaid interest expense of $24,061 from earlier periods, an increase in the interest rate to 10% per annum, an upfront payment of $40,000 made at signing, and a requirement for minimum monthly payments of $25,000. Additionally, the maturity date has been extended to May 31, 2025. ~~As of June 30, 2025, the outstanding balance of the Promissory Note was $595,259.~~

On August 4, 2025, the Company amended the terms of its Promissory Note with Benesch Friedlander Coplan & Aronoff. The ~~outstanding~~amended terms include an updated principal balance of ~~Short-term~~$621,732, ~~Notes~~which ~~Payable~~includes unpaid interest expense from earlier periods, an interest rate to 10% per annum and the maturity date ~~amounted~~has been extended to December 31, 2025. As of September 30, 2025, the outstanding balance of the Promissory Note was $1621,~~875~~732 and 634,~~290~~627 as of September 30, 2025 and December 31, 2024. The accrued but unpaid interest on the Promissory Note totaled approximately $115,~~917~~803 and $3,~~962~~304 as of ~~June~~September 30, 2025 and December 31, 2024, respectively.

OnThe outstanding ~~August~~balance ~~4, 2025, the Company amended the terms~~ of ~~its~~Short-term ~~Promissory Note~~Notes ~~with~~Payable ~~Benesch~~amounted ~~Friedlander~~to ~~Coplan~~$1,905,067 &and ~~Aronoff. The amended terms include an updated principal balance of~~ $~~621~~1,~~732~~917,962 ~~which~~as ~~includes unpaid~~of ~~interest~~September ~~expense from earlier periods~~30, an2025 ~~interest rate to 10% per annum~~ and ~~the maturity date has been extended to~~ December 31, 2024, ~~2025~~respectively.

Great Point Capital, LLC

On October 29, 2025, the Company executed a unsecured Promissory Note with Great Point Capital, LLC (the “Noteholder”) in the principal amount of $1,000,000. The Note bears interest at a rate of 8.0% per annum, payable quarterly in arrears. The Note matures on October 25, 2026 or the date on which all amounts become immediately due and payable following a Nasdaq delisting notice that would result in the Company’s common stock no longer trading on any Nasdaq market. In the event of a default, the Note bears interest at the Default Rate of 10% per annum.

The Note contains customary representations, warranties, and covenants of the Company and provides for events of default, including nonpayment of principal or interest, breaches of representations, insolvency events, and delisting of the Company’s common stock from Nasdaq. Upon an event of default, the Noteholder may declare all outstanding principal and accrued interest immediately due and payable.

NOTE 11 — INCOME TAXES

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of ~~June~~September 30, 2025, and December 31, 2024, the Company had a full valuation allowance against its deferred tax assets.

For the three and ~~six~~ nine months ended ~~June~~September 30, 2025, the Company utilized the annualized effective tax rate method and recorded zero income tax expense based on a zero effective tax rate. No tax benefit or expense has been recorded in relation to the pre-tax income for the ~~three~~nine ~~and six~~ months ended September ~~June~~ 30, 2025, and pre-tax losses for the three months ended ~~June~~September 30, ~~2024,~~ 2025 and ~~pre-tax~~three ~~losses~~and ~~for~~nine ~~the six~~ months ended ~~June~~September 30, 2024 due to a full valuation allowance to offset any deferred tax assets.

25On July 4, 2025, the U.S. enacted the One Big Beautiful Bill Act (“the Act”), which includes several corporate tax provisions, such as 100% bonus depreciation on qualified property and the immediate deductibility of domestic research and experimental expenditures. The provisions of the Act did not have a material impact on our income tax expense or effective tax rate.

NOTE 12 — STOCK-BASED COMPENSATION

Unrestricted Common Stock Awards

During the ~~six~~nine months ended ~~June~~September 30, 2025, the Company granted unrestricted common shares to certain in connection with the terms of their individual employment agreements. As these awards were fully-vested, unrestricted shares, the Company recognized the full amount of $0 and $121,410 for the three and ~~six~~nine months ended ~~June~~September 30, 2025, respectively. This compensation cost is included within Research and Development expenses on the Company’s condensed consolidated and combined statements of operations.

During the three and six months ended June 30, 2024, the Company granted no unrestricted common shares and 300,000 unrestricted common shares, respectively, to certain executives in connection with the terms of their individual employment agreements. As these awards were fully-vested, unrestricted shares, the Company recognized the full amount of $0 and $1,359,000 for the three and six months ended June 30, 2024, respectively. This compensation cost is included within Selling, General, and Administrative expenses on the Company’s condensed, consolidated and combined statements of operations.26

During the three and nine months ended September 30, 2024, the Company granted no unrestricted common shares and 300,000 unrestricted common shares, respectively, to certain executives in connection with the terms of their individual employment agreements. As these awards were fully-vested, unrestricted shares, the Company recognized the full amount of $0 and $1,359,000 for the three and nine months ended September 30, 2024, respectively. This compensation cost is included within Selling, General, and Administrative expenses on the Company’s condensed, consolidated and combined statements of operations.

Restricted Stock Units and Stock Options

During the ~~six~~nine months ended ~~June~~September 30, 2025, the Company granted restricted stock units to certain executives and management in connection with the terms of their individual employment agreements. The Company recognized the amount of $~~111~~71,~~334~~049 and $~~280~~351,~~108~~157 for the three and ~~six~~nine months ended ~~June~~September 30, 2025, respectively. This compensation cost is included within Research and Development expenses on the Company’s condensed consolidated and combined statements of operations. There were no stock options granted or outstanding during the period ended ~~June~~September 30, 2025.

There were no restricted stock units or stock options granted during the three and ~~six~~nine months ended ~~June~~September 30, 2024. Additionally, there were no restricted stock units or stock ~~options~~ options outstanding at either the beginning or the end of the periods ended ~~June~~September 30, 2024.

Warrants

During the three and ~~six~~nine months ended ~~June~~ September 30, 2025, the Company granted 0 and 12,000 at-the-money warrants, respectively, to certain executive officers pursuant to the terms of their individual employment agreements. The warrants were fully vested upon grant and expire on February 2, 2029, however, the exercise price has not been established.

There were no warrants granted during the ~~three~~ three and ~~six~~nine months ended ~~June~~September 30, 2024. Additionally, there were no warrants outstanding at either the beginning or the end of the ~~periods~~ periods ended ~~June~~September 30, 2024.

Awards with Market-Based Conditions

In connection with the aforementioned executive employment agreements, certain executives are eligible to receive unrestricted shares of common stock if certain stock price targets are met during the term of the respective employment agreements. A stock price target will be satisfied if the 120-day trailing average closing price (based on trading days) of a share of the Company’s common stock equals or exceeds the applicable stock price target, which range from $30 1,500 to $~~300~~15,000 per share. The executives could be granted up to 120,000 shares based on attainment of all applicable stock price targets over the term of six years and an estimated fair value of approximately $4,800,000. The Company recorded $278,176, $~~556~~834,~~352~~529, $~~451~~278,~~662~~176 and $~~451~~729,~~662~~ 839 of expense related to these awards for the three and ~~six~~nine months ended ~~June~~September 30, 2025 and 2024, respectively. This compensation cost is included within Selling, General, and Administrative expenses on the Company’s condensed consolidated and combined statements of operations.

The following table summarizes our awards with market-based conditions:

	Number of Shares		Weighted Average Grant-Date Fair Value
Beginning of period		-		-
Granted		120,000	$	40.00
Vested		-		-
Cancelled		-		-
End of period		120,000	$	40.00

Awards with Performance Conditions

In connection with the aforementioned executive employment agreements, certain executives are eligible to receive cash incentive payments in connection with the Company achieving certain capital raise targets. In addition, these executives can also receive a cash bonus equal to 2.5% of the equity value of the Company (up to $10 million for each executive, totaling $20 million) in an applicable sale of the Company as defined by the terms of the employment agreements. Through ~~June~~September 30, 2025, it was not considered probable that either performance condition would be achieved, and therefore no no expense was recorded related to these awards.

2627

NOTE 13 — FAIR VALUE MEASUREMENTS

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

Level 1—quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3—unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

The following table presents information about the Company’s liabilities that are measured at fair value as of ~~June~~September 30, 2025 and December 31, 2024 and indicates the fair ~~value~~ value hierarchy of the valuation inputs the Company utilized to determine such fair value:

			June 30,			December 31,
				September 30,			December 31,
Description:	Level		~~2025~~	2025		~~2024~~	2024
Derivative Liabilities:
Forward purchase agreement	3	3	$	~~752,600~~$	886,000	$	~~6,404,100~~$	6,404,100
Warrants – Series A	3	3	$	~~527,100~~$	2,715,900	$	~~4,955,300~~$	4,955,300
Warrants – Series C and D	3	3	$	~~9,531,000~~$	11,706,500	$	~~13,913,250~~$	13,913,250

Forward purchase agreement

The Company used a Monte Carlo analysis to determine the fair value of the FPA, assuming 191,007 FPA Shares.

2728

The fair value measurement of the FPA at ~~June~~September 30, 2025 and December 31, 2024 was calculated using the following range of weighted average assumptions:

	June 30,			December 31,
	September 30,			December 31,
	2025			2024
Risk-free interest rate		3.8265	%		4.25	%
Stock price	$	34.9464		$	35.00
Expected life		1.63 years			2.1 years
Expected volatility of underlying stock		~~150~~157.05	%		105.0	%
Dividends		0	%		0	%

The model measured the total present value of the Company’s proceeds at approximately $23,~~811~~777 and the total present value of the Company’s liability at approximately $~~755~~889,~~425~~739, resulting in a net liability of approximately $~~752~~886,~~600~~000 as of ~~June~~September 30, 2025. As a result, the Company recognized non-cash ~~gains~~gain (loss) from changes in the fair value of derivatives of $~~381~~(133,~~800~~400) and $5,~~651~~518,~~500~~100 for the three and ~~six~~nine months ended ~~June~~September 30, 2025, respectively, compared to $151,~~824~~413,~~800~~ 700 and $1617,~~074~~487,~~150~~850 for the three and ~~six~~nine months ended ~~June~~September 30, 2024.

Warrants – Series A and B

The Company utilized a Monte Carlo simulation analysis to determine the fair value of the Series A Warrants and Series B Warrants at the date of issuance (March 15, 2024), which included the following assumptions:

	Series A Warrants			Series B Warrants
Expected term (in years)		5.7 years			5.7 years
Stock price	$	87.00		$	87.00
Risk free rate		4.2	%		4.2	%
Expected volatility		82.5	%		82.5	%
Expected dividend rate	$	0.00		$	0.00
Exercise Price	$	37.50		$	0.01

The total fair value of the Series A Warrants and Series B Warrants measured at issuance was $12,656,550 and $82,450, respectively.

The Company utilized a Monte Carlo simulation analysis to determine the fair value of the Series A Warrants at ~~June~~September 30, 2025, which included the following assumptions:

	Series A Warrants
Expected term		4.42 years
Stock price	$	34.9464
Risk free rate		3.97	%
Expected volatility		~~135~~145.0	%
Expected dividend rate	$	0.00
Exercise Price	$	3.10

28The fair value of the Series A and Series B Warrants as of September 30, 2025, was $2,715,900 and $0, respectively. The $0 fair value for the Series B Warrants reflects that all Series B Warrants had been exercised by this date. The Company recorded non-cash gain (loss) from changes in the fair value of derivative liabilities related to the Series A and Series B Warrants of $71,850 and $2,239,400 for the three and nine months ended September 30, 2025, respectively, compared to $5,383,585 and $6,093,635 for the three and nine months ended September 30, 2024. As of September 30, 2025, investors had exercised 447,145 Series A Warrants and 114,992 Series B Warrants, resulting in the issuance of 562,137 common shares. As of September 30, 2025, 652,857 Series A Warrants and no Series B Warrants remained outstanding.

The fair value of the Series A and Series B Warrants as of June 30, 2025, was $527,100 and $0, respectively. The $0 fair value for the Series B Warrants reflects that all Series B Warrants had been exercised by this date. The Company recorded non-cash gains from changes in the fair value of derivative liabilities related to the Series A and Series B Warrants of $162,400 and $4,428,200 for the three and six months ended June 30, 2025, respectively, compared to $9,141,900 and $710,050 for the three and six months ended June 30, 2024. As of June 30, 2025, investors received 289,613 and 114,992 common shares from exercise of Series A and Series B warrants, respectively. As of June 30, 2025, 153,221 Series A Warrants and no Series B Warrants remained outstanding.

Warrants – Series C and D

The Company utilized a Monte Carlo simulation analysis to determine the fair value of the Series C Warrants and Series D Warrants at the date of issuance on August 30, 2024, which included the following assumptions:

	Series C Warrants			Series D Warrants
Expected term		5.6 years			5.6 years
Stock price	$	16.00		$	16.00
Risk free rate		3.7	%		3.7	%
Expected volatility		105.0	%		105.0	%
Expected dividend rate	$	0.00		$	0.00
Exercise Price	$	16.37		$	0.0050

The total fair value of the Series C Warrants and Series D Warrants measured at issuance was $8,114,650 and $1,540,150, respectively.

The Company utilized a Monte Carlo simulation analysis to determine the fair value of the Series C Warrants and Series D Warrants at June 30, 2025, which included the following assumptions:

	Series C Warrants			Series D Warrants
Expected term (in years)		5.7 years			5.7 years
Stock price	$	3.94		$	3.94
Risk free rate		3.9	%		3.9	%
Expected volatility		135.0	%		135.0	%
Expected dividend rate	$	0.00		$	0.00
Exercise Price	$	3.25		$	0.0050

The fair value of the Series C Warrants and Series D Warrants as of June 30, 2025, was $7,037,100 and $2,493,900, respectively. This resulted in non-cash gains from the change in fair value of derivatives of $1,500,300 and $4,382,250, for the three and six months ended June 30, 2025. As of June 30, 2025, investors have not exercised any Series C and Series D warrants.

The ~~table~~total ~~below~~fair ~~provides a~~value ~~summary~~ of the ~~changes~~Series inC ~~fair value, including net transfers in~~ Warrants and~~/or~~ ~~out,~~Series ofD ~~all~~Warrants ~~financial assets and liabilities~~ measured at ~~fair value~~issuance onwas a$8,114,650 ~~recurring basis using significant unobservable inputs (Level 3) during the three~~ and ~~six months ended June 30~~$1,540,150, ~~2025~~respectively.

	Fair Value
	Measurement
	Using Level 3
Forward Purchase Agreement	Inputs Total
Balance, December 31, 2024	$	6,404,100
Change in fair value		(5,269,700	)
Balance, March 31, 2025		1,134,400
Change in fair value		(381,800	)
Balance, June 30, 2025		752,600

The Company utilized a Monte Carlo simulation analysis to determine the fair value of the Series C Warrants and Series D Warrants at September 30, 2025, which included the following assumptions:

	Fair Value
	Series C Warrants			Series D Warrants
	Measurement
Expected term (in years)		5.6 years			5.6 years
	Using Level 3
Stock price	$	4.64		$	4.64
Warrants – Series A	Inputs Total
Risk free rate		3.7	%		3.7	%
Balance, December 31, 2024	$	4,955,300
Expected volatility		145.0	%		145.0	%
Change in fair value		(4,265,800	)
Expected dividend rate	$	0.00		$	0.00
Balance, March 31, 2025		689,500
Exercise Price	$	3.25		$	0.0050
Change in fair value		(162,400	)
Balance, June 30, 2025		527,100

	Fair Value
	Measurement
	Using Level 3
Warrants – Series C and D	Inputs Total
Balance, December 31, 2024	$	13,913,250
Change in fair value		(2,881,950	)
Balance, March 31, 2025		11,031,300
Change in fair value		(1,500,300	)
Balance, June 30, 2025		9,531,000

The fair value of the Series C Warrants and Series D Warrants as of September 30, 2025, was $8,684,300 and $3,022,200, respectively. This resulted in non-cash gain (loss) from the change in fair value of derivatives of $(2,175,500) and $2,206,750, for the three and nine months ended September 30, 2025, compared to $435,550 for the three and nine months ended September 30, 2024. As of September 30, 2025, investors have not exercised any Series C and Series D warrants.

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three and nine months ended September 30, 2025.

	Fair Value
	Measurement
	Using Level 3
Forward Purchase Agreement	Inputs Total
Balance, December 31, 2024	$	6,404,100
Change in fair value		(5,269,700	)
Balance, March 31, 2025		1,134,400
Change in fair value		(381,800	)
Balance, June 30, 2025		752,600
Change in fair value		133,400
Balance, September 30, 2025		886,000

	Fair Value
	Measurement
	Using Level 3
Warrants – Series A	Inputs Total
Balance, December 31, 2024	$	4,955,300
Change in fair value		(4,265,800	)
Balance, March 31, 2025		689,500
Change in fair value		2,098,250
Balance, June 30, 2025		2,787,750
Change in fair value		(71,850	)
Balance, September 30, 2025		2,715,900

	Fair Value
	Measurement
	Using Level 3
Warrants – Series C and D	Inputs Total
Balance, December 31, 2024	$	13,913,250
Change in fair value		(2,881,950	)
Balance, March 31, 2025		11,031,300
Change in fair value		(1,500,300	)
Balance, June 30, 2025		9,531,000
Change in fair value		2,175,500
Balance, September 30, 2025		11,706,500

HBC earnout shares

The Company utilized a Monte Carlo simulation analysis to determine the fair value of the Earnout Shares at the date of the Merger, which included the following assumptions: stock price of $226.50, risk free rate of 3.98%, volatility of 85%, dividends yield of 0% and duration of 4 years.

Stock-based compensation – Awards with Market-Based Conditions

The Company utilized a Monte Carlo simulation analysis to determine the fair value of the awards with market-based conditions at the date of the Merger, which included the following assumptions: stock price of $226.50, risk free rate of 3.9%, volatility of 72.5%, dividends yield of 0% and duration of 6 years.

NOTE 14 — SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company did not identify any subsequent events, except as noted below, that would have required adjustment or disclosure in the financial statements.

~~Benesch~~Warrant ~~Note~~Conversion and Related Transactions

On ~~August~~October 48, 2025, ~~the~~Madison ~~Company~~Bond ~~amended~~LLC and Bayside Project LLC (together, the ~~terms~~“New Holders”) acquired from prior holders all of ~~its~~the ~~Promissory~~Company’s outstanding Series C and ~~Note~~Series ~~with~~D ~~Benesch~~warrants ~~Friedlander~~previously ~~Coplan~~issued &by ~~Aronoff.~~the ~~The~~Company ~~amended~~pursuant ~~terms~~to ~~include~~the anAugust ~~updated~~Subscription ~~principal~~Agreement ~~balance~~dated ofAugust ~~$621~~30,~~732,~~ ~~which~~2024. ~~includes~~Immediately thereafter, ~~unpaid~~the ~~interest~~Company ~~expense~~invoked ~~from~~conversion ~~earlier~~provisions ~~periods,~~contained anin ~~interest~~the ~~rate~~Warrants toand ~~10%~~the ~~per~~Purchase ~~annum~~Agreement and ~~the~~converted ~~maturity~~all ~~date~~unexercised ~~has~~portions of ~~been~~the ~~extended~~Warrants tointo ~~December~~an 31aggregate of 3,447,957 shares of the Company’s common stock (the “Conversion”). Following the ~~2025~~Conversion, all Series C and Series D warrants were cancelled.

30In connection with the Conversion, the Purchasers and the Company amended the Original Purchase Agreement to remove or modify certain financing restrictions, including limitations on future equity issuances and participation rights, subject to agreed-upon dilution protections. The Purchasers also entered into a lock-up agreement restricting the sale or transfer of their shares for a period of 12 months following the Effective Date, subject to limited exceptions. As a result of the Conversion, the Purchasers collectively hold approximately 47.5% of the Company’s outstanding common stock and are the Company’s largest stockholders. The transaction constituted a change in control of the Company under SEC Regulation S-K Item 403.

On October 23, 2025, the Company issued 3,447,957 shares of its common stock to the New Holders pursuant to a 12-month lock-up agreement.

Issuance of Shares for HBC Earn-out

On October 9, 2025, the Company issued 450,000 shares of common stock to G3 pursuant to an earn-out provision under the Company’s February 2, 2024 merger agreement. As a result of these issuances, G3 beneficially owns approximately 24.2% of the Company’s outstanding common stock. See Note 1 for more details.

Issuance of Shares to Non-executive Directors and Certain Employees

On October 9, 2025, the Company issued 40,000 bonus shares of Common Stock to each of its non-executive directors, John Davis and Karin-Joyce Tjon, and its former non-executive director Cynthia Ekberg Tsai. The issuances were in consideration of their prior board service from the closing of the Company’s business combination on February 2, 2024 until one year thereafter. The issuances were pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. No underwriting discounts or commissions were paid with respect to such issuances.

On October 9, 2025, the Company issued 120,000 bonus shares of Common Stock to certain of its employees that are not executive officers. The issuances were in consideration of their prior service to the Company from the closing of the Company’s business combination on February 2, 2024 until one year thereafter. The issuances were pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. No underwriting discounts or commissions were paid with respect to such issuances.

Promissory Note with Great Point Capital, LLC

On October 29, 2025, the Company entered into a Promissory Note with Great Point Capital, LLC in the principal amount of $1,000,000. The Note bears interest at 8.0% per annum, payable quarterly, and matures on October 25, 2026. The proceeds will be used for general corporate purposes, including working capital needs. See Note 10 for more details.

Nasdaq Capital Market Listing Approval

On October 29, 2025 the Company was notified by NASDAQ staff that Company’s application to list its Common Stock on The Nasdaq Capital Market was approved. The Company’s securities were transferred to the Capital Market at the opening of business on October 31, 2025. As a result, all matters pertaining to Nasdaq’s MVLS and MVPHS deficiencies are now closed.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Solidion Technology, Inc. References to our “management” or our “management team” refer to our officers and directors. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

Overview

Solidion Technology, Inc. is an advanced battery technology company focused on the development and commercialization of next-generation battery materials, components, and energy storage solutions. Headquartered in Dallas, Texas, with research and development (R&D) and manufacturing operations in Dayton, Ohio, Solidion is dedicated to transforming the energy storage landscape by addressing key limitations in current lithium-ion and emerging battery technologies.

The Company specializes in high-performance silicon-rich anode materials, solid-state battery technology, and fire-retardant electrolytes, aiming to enhance the energy density, safety, and cost-effectiveness of lithium-ion batteries. Solidion’s proprietary innovations include graphene-enabled batteries, elastomer-protected electrodes, quasi-solid and solid-state electrolytes, and biochar-derived anode materials, providing sustainable and scalable solutions for the electric vehicle (EV), energy storage system (ESS), and consumer electronics markets.

Solidion holds an extensive intellectual property (IP) portfolio with over 525 active patents (pending and granted) globally, positioning the Company as a leader in silicon anode and solid-state battery technology. Its innovative silane-free production processes for silicon-based anode materials allow for lower manufacturing costs and improved scalability. Additionally, its fire-retardant and polymer-based electrolytes enable safer, high-energy-density batteries compatible with existing lithium-ion cell production infrastructure.

A key milestone in Solidion’s technological advancements is the successful development of a high-energy cylindrical cell, which achieves an exceptional energy density of 305 Wh/kg, significantly higher than conventional lithium-ion batteries, which typically range between 240-260 Wh/kg. This innovation not only enhances the range and performance of EVs but also underscores Solidion’s ability to deliver cutting-edge solutions for high-energy and high-power applications.

The Company has established strategic partnerships with leading industry players, including Giga Solar Materials Corp. and Bluestar Materials Company, to advance the production and commercialization of silicon oxide (SiOx) anode materials in the U.S. These collaborations, along with Solidion’s ongoing engagement with EV original equipment manufacturers (OEMs) and toll-manufacturing partners, position the Company to accelerate the adoption of its next-generation battery solutions.

On November 14, 2024, we adopted a strategic Bitcoin allocation policy for our Corporate Treasury. As part of this strategy, Solidion is committed to leveraging Bitcoin as a long-term store of value. The Company will allocate excess cash from operations toward Bitcoin purchases, subject to board approval. Additionally, interest earnings from cash held in money market accounts will be converted into Bitcoin. The Company also plans to allocate a portion of future capital raises to Bitcoin acquisitions, demonstrating a sustained commitment to integrating Bitcoin into its financial strategy. For fiscal year 2024, the Company did not identify excess cash from operations for Bitcoin purchases. Additionally, $13,806 generated in interest income earnings during fiscal year 2024 have been designated for Bitcoin purchases in fiscal year 2025 as part of the ongoing treasury strategy. The Company did not conduct any capital raise activities between the date of its announcement and the end of the reporting period and, as a result, did not allocate any proceeds toward Bitcoin purchases. Looking ahead, during fiscal year 2025, Solidion anticipates capital raises that will include allocation of a portion of proceeds to Bitcoin acquisitions.

Solidion is committed to advancing battery technology through continuous R&D efforts, expanding manufacturing capabilities, and optimizing supply chain sustainability. By integrating cutting-edge materials and scalable production methods, Solidion aims to deliver high-performance, cost-effective, and environmentally sustainable battery solutions that address the increasing demand for electrified mobility and renewable energy storage.

3132

Our Products

Anode Materials Our product portfolio includes graphite-based anode materials, distinguished by our commitment to utilizing raw materials from sustainable sources. As part of our efforts to contribute to the goal of net-zero greenhouse gas emissions by 2050, we are scrutinizing our entire supply chain to identify opportunities for reducing environmental impacts. Graphite, a critical component in rechargeable batteries due to its longevity and cost-efficiency, is traditionally derived from petroleum coke and pitch. Solidion’s innovative approach introduces biochar produced from waste biomass as an alternative feedstock. This sustainable process not only sequesters carbon but may also result in carbon-negative production. By leveraging biochar, Solidion aims to produce anode-grade graphite with exceptional performance. By the end of 2024, Solidion’s anode materials containing biochar-derived materials have achieved a capacity of over 340 mAh/g and comparable cycle life to conventional graphite anodes, marking a significant step towards more environmentally responsible battery manufacturing. Solidion has also developed a series of silicon and SiOx anode materials that enable a significantly higher energy density (for example, an expected 20-30% increase in the EV driving range) likely at a reduction in the cell cost in terms of U.S. dollars per kilowatt hour (“kWh”) when production in scale occurs. The specific capacity of these products range from 1,300 to 2,800 mAh/g aiming to suit different applications including EV, energy storage stations, drones, and consumer electronics.

Battery Cells To rigorously validate the performance of its innovative anode materials, Solidion is actively engaged in the development and testing of a diverse portfolio of battery cells. By the close of 2024, Solidion, in collaboration with strategic partners, has successfully constructed and evaluated over three distinct types of cylindrical cells, each featuring either our advanced silicon (Si) or graphite-based anodes. These cells showcase a wide range of capabilities, with capacities spanning from 4.6 to an impressive 5.5Ah.

Notably, our high-energy 5.5Ah 21700 cylindrical cell represents a significant leap forward in battery technology. This cell not only achieves an exceptional energy density of 305 Wh/kg, surpassing the typical 240-260 Wh/kg offered by established Asian manufacturers in the same high-energy category, but also delivers superior power performance. It boasts a continuous charging and discharging capability exceeding 2C, a substantial improvement over the performance less than 1C typically seen in competitor products. This combination of high energy density and robust power handling makes our 5.5Ah cell ideally suited for applications demanding both sustained energy delivery and moderate to high power output, such as advanced electric vehicles and high-performance portable electronics.

Furthermore, Solidion is actively developing cell variants tailored for applications requiring even higher power capabilities. These cells have already demonstrated impressive fast-charging capabilities, exceeding 3C, enabling rapid replenishment of energy and minimizing downtime. This focus on high-power cells underscores our commitment to addressing the diverse needs of the evolving energy storage market.

Beyond anode advancements, Solidion is also pioneering the development of next-generation electrolytes. As previously mentioned, we have successfully formulated fire-retardant and quasi-solid electrolytes, demonstrating their performance through the construction of small prototype cells. These electrolytes represent a significant step towards enhancing battery safety, a critical consideration in today’s demanding applications. Looking ahead, Solidion intends to scale up production of these electrolyte-based cells, manufacturing larger format cells in common practical sizes. This initiative will not only validate the performance of our advanced electrolytes in real-world scenarios but also pave the way for the development of safer and more reliable energy storage solutions. By integrating our innovative anode materials with these advanced electrolytes, Solidion is poised to deliver a new generation of high-performance, safe, and sustainable batteries. The development of larger cells with advanced electrolytes is scheduled to conclude in 2025.

Recent Developments

Honeycomb Battery Company Merger

On February 2, 2024, Nubia Brand International Corp., a Delaware corporation (“Nubia” and after the Transactions described herein, “Solidion” or “Solidion Technology, Inc.”), consummated a merger (the “Closing”) pursuant to a Merger Agreement, dated February 16, 2023 (as amended on August 25, 2023, the “Merger Agreement”), by and among Nubia, Honeycomb Battery Company, an Ohio corporation (“HBC”), and Nubia Merger Sub, Inc., an Ohio corporation and wholly-owned subsidiary of Nubia (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into HBC (the “Merger,” and the transactions contemplated by the Merger Agreement, the “Transactions”), with HBC surviving such merger as a wholly owned subsidiary of Nubia, which was renamed “Solidion Technology, Inc.” upon Closing.

We received net proceeds from the Merger totaling $17,555. The Company is applying the proceeds from the Merger toward its corporate growth strategy related to the commercialization of our battery technology and the scaling of its manufacturing operations.

Equity Financing

On March 13, 2024, Solidion entered into a private placement transaction (the “March Private Placement”), pursuant to a Securities Purchase Agreement (the “March Subscription Agreement”) with certain institutional investors (the “Purchasers”) for aggregate gross proceeds of $3,850,000, before deducting fees to the placement agent and other expenses payable by the Company in connection with the March Private Placement. The net proceeds from the March Private Placement were used for working capital and general corporate purposes. The March Private Placement closed on March 15, 2024.

3233

As part of the March Private Placement, the Company issued an aggregate of 102,667 units and pre-funded units (collectively, the “Units”) at a purchase price of $37.50 per unit (less $0.0050 per pre-funded unit). Each Unit consists of (i) one share of Solidion Common Stock, (ii) two Series A warrants (“Series A Warrants”) each to purchase one share of Common Stock, and (iii) one Series B warrant (“Series B Warrants”) to purchase such number of shares of Common Stock as determined on the reset date, and in accordance with the terms therein.

The reset period ended on July 2, 2024 (the “Reset Date”), with the lowest 10-day VWAP on June 28, 2024, being $0.4347. Consequently, the reset ~~price~~ price was established at $17.39. As a result, the Series A Warrants and Series B Warrants held by investors were reset to 442,834 shares ~~and~~ and 114,992 shares, respectively. As of ~~June~~September 30, 2025, investors had exercised ~~289~~447,~~613~~145 Series A Warrants and 114,992 Series B Warrants, ~~resulting~~ resulting in the issuance of ~~404~~562,~~605~~137 common shares. On May 12, 2025, the Company effected a 1-for-50 reverse stock split of its common stock. Following the reverse split, the 5-day reset period ended on May 19, 2025, with the lowest 5-day VWAP on May 14, 2025, being $3.0951. Consequently, the reset price was established at $3.0951, and the Series A Warrants held by investors were reset to 810,389 shares. The Series B Warrants were not subject to a post-split reset because no Series B Warrants were outstanding at the time the reverse stock split became effective. As of ~~June~~September 30, 2025, ~~153~~652,~~221~~857 Series A Warrants and no Series B Warrants remained outstanding.

On August 30, 2024, the Company entered into a private placement transaction (the “August Private Placement”), pursuant to a Securities Purchase Agreement (the “August Subscription Agreement”) with certain institutional investors (the “Purchasers”) for aggregate gross proceeds of $4,000,000, before deducting fees to the placement agent and other expenses payable by the Company in connection with the August Private Placement. The Company intends to use the net proceeds from the August Private Placement for working capital and general corporate purposes.

As part of the August Private Placement, the Company issued an aggregate of 244,349 units and pre-funded units (collectively, the “Units”) at a purchase price of $16.37 per unit. Each Unit consists of (i) one share of common stock, par value $0.~~0050~~0001 per share of the Company (the “Common Stock”) (or one pre-funded warrant to purchase one share of Common Stock (the “Pre-Funded Warrant”)), (ii) two Series C warrants each to purchase one share of Common Stock (the “Series C Warrant”) and (iii) one Series D warrant to purchase such number of shares of Common Stock as determined on the Reset Date (as defined in Note 10) and in accordance with the terms therein (the “Series D Warrant” and together with the Pre-Funded Warrant and the Series C Warrant, the “Warrants”).

Components of Results of Operations

Revenue

The Company is focused on commercializing and manufacturing battery materials and next-generation battery cells. Historically, and during the periods presented, we have generated minimal revenue from product samples. We do not expect to begin generating significant revenue until we complete the commercialization process and build out manufacturing capacity. Future capacity may come from joint ventures with strategic partners, sourcing third-party manufacturing from our network, or pursuing mergers and acquisitions.

Operating Expenses

Research and Development

Research and development expenses consist primarily of personnel expenses, including salaries, benefits, third party technology validation testing, equipment, engineering, maintenance of facilities, data analysis, and materials.

Selling, general and, administrative

Selling, general and administrative expenses primarily consist of personnel expenses, including salaries, benefits, and stock-based compensation related to executive management, finance, legal, and human resource functions. Other costs include business development, contractor and professional services fees, audit and compliance expenses, insurance costs and general corporate expenses, such rent, office supplies and information technology costs.

Other Income (Loss)

Change in fair value of Derivative Liabilities

Change in fair value of Derivative Liabilities consists of fluctuations in the fair value of an agreement between the Company and investors facilitating future purchases of the Company’s stock by the Investor based on a Monte Carlo simulation model.

Interest Income

Interest income is derived from the Company’s operating cash account, which is periodically invested in short-term money market funds.

Interest Expense

Interest expense consists primarily of the interest on the Company’s short-term notes and D&O insurance premium financing arrangement.

Results of Operations

This data should be read in conjunction with Solidion’s financial statements and accompanying notes. These results of operations are not necessarily indicative of future performance.

Summary of Statements of Operations for the Three Months Ended ~~June~~ September 30, 2025 and 2024

	For the Three Months Ended June 30,
	For the Three Months Ended September 30,
	2025			2024
Net sales	$	49,~~000~~350		$	-
Cost of goods sold		24,~~327~~321			-
Operating expenses		1,~~788~~747,~~797~~929			24,~~933~~193,~~309~~006
Total other income (expense)		1(2,~~933~~349,~~915~~245	)		24(2,~~951~~443,~~725~~673	)
Net income (loss)	$	~~146~~(4,~~791~~092,145	)	$	22(6,~~018~~636,~~416~~679	)

Operating Expenses

Operating expenses decreased by $12,~~144~~445,~~512~~077 for the three months ended ~~June~~September 30, 2025. This decrease was driven by lower Selling, General and Administrative expenses, including reductions in professional fees, stock-based compensation, insurance costs, and other administrative expenses associated with the Company’s operations as a public entity beginning February 2, 2024.

Other Income (expense)

Other income ~~decreased~~increased by $2394,~~017,810~~428 for the three months ended ~~June~~ September 30, 2025. This ~~decrease~~increase was largely driven by reduced non-cash ~~gains~~losses due to aissuance ~~change in the fair value~~ of ~~derivative~~common ~~liabilities~~stock ~~related to the Forward Purchase Agreement,~~ and warrants related to the ~~March and~~ August ~~private~~Private ~~placement~~Placement financing. Additionally, there was interest expense of $112,~~471~~371 primarily related to the Company’s short-term notes.

34Summary of Statements of Operations for the Nine Months Ended September 30, 2025 and 2024

Summary of Statements of Operations for the Three Months Ended June 30, 2025 and 2024

	For the Nine Months Ended September 30,
	2025		2024 (Restated)
Net sales	$	13,350	$	-
Cost of goods sold		6,648		-
Operating expenses		6,669,395		10,885,651
Total other income (expense)		10,676,719		(6,268,594	)
Net income (loss)	$	4,014,026	$	(17,154,245	)

	For the Six Months Ended June 30,
	2025		2024
Net sales	$	4,000	$	-
Cost of goods sold		2,327		-
Operating expenses		4,921,466		6,692,645
Total other income (expense)		14,261,214		(3,824,921	)
Net income (loss)	$	9,341,421	$	(10,517,566	)

Operating Expenses

Operating expenses decreased by $14,~~771~~216,~~179~~256 for the ~~six~~nine months ended ~~June~~September 30, 2025. This decrease was primarily driven by lower professional fees, stock-based compensation, insurance, and other administrative costs associated with the Company operating as a public entity as of February 2, 2024.

Other Income (expense)

Other income increased by $1815,~~086~~919,~~135~~913 for the nine ~~six~~ months ended ~~June~~ September 30, 2025. This increase was largely driven by a gain of $149,~~461~~964,~~950~~250 due to a change in the fair value of derivative liabilities related to the Forward Purchase Agreement, and warrants related to the Private Placement financing. Additionally, there was interest expense of $~~218~~331,~~893~~264 primarily related to the Company’s short-term notes.

Cash Flows

The following tables set forth a summary of our cash flows for the periods indicated

	For the Six Months Ended June 30,
	For the Nine Months Ended September 30,
	2025			2024 (Restated)
Net cash provided by (used in):
Operating Activities		(3,~~255~~607,~~997~~781	)		(35,~~541~~677,~~372~~192	)
Investing Activities		(~~181~~213,~~498~~882	)		(~~157~~190,~~834~~931	)
Financing Activities		~~198~~628,~~415~~437			37,~~954~~056,~~930~~000
Net increase (decrease) in cash		(3,~~239~~193,~~080~~226	)		~~255~~1,~~724~~187,877

Net Cash used in Operating Activities

For the ~~six~~nine months ended ~~June~~September 30, 2025, cash used in operating activities was $3,~~255~~607,~~997~~781. This primarily resulted from net income of $92,~~341~~988,~~421~~626, which included non-cash gain of $149,~~461~~964,~~950~~250 due to a change in the fair value of derivative liabilities related to the Forward Purchase Agreement and March and August Private Placement warrants. These non-cash gains were added back to reconcile net income to net cash used in operating activities, as part non-cash adjustments that also included depreciation and amortization, stock-based compensation non-cash interest expense, totaling $138,~~162~~449,~~090~~626. Additionally, changes in operating assets and liabilities used $~~564~~1,~~672~~853,219 of cash from operating activities, driven primarily by a $~~431~~2,~~608~~134,207 increase in ~~other current~~Accounts ~~assets.~~payable ~~The increase in other current assets was due to the financing arraignment associated with the directors~~ and ~~officers~~accrued ~~insurance policy~~expenses.

For the ~~six~~nine months ended ~~June~~September 30, 2024, cash used in operating activities was $35,~~541~~677,~~372~~192. This primarily resulted from a net loss of $1017,~~517~~154,~~566~~245, which included significant non-cash ~~gains~~ gains and losses, driven by a gain of $1624,~~784~~017,~~200~~035 due to a change in the fair value of derivative liabilities related to the Forward Purchase Agreement and Private Placement warrants, and a loss of $2030,~~590~~245,~~717~~516 from the issuance of common stock and warrants related to the convertible note and private placement financing activity. These non-cash losses were added back to reconcile net loss to net cash used in operating activities, as part non-cash adjustments that also included depreciation and amortization and stock-based compensation, totaling $510,~~814~~342,~~482~~124. Additionally, changes in operating assets and liabilities provided $1,~~161~~134,~~712~~929 of cash from operating activities.

Net Cash used in Investing Activities

For the ~~six~~nine months ended ~~June~~September 30, 2025, the Company used cash of $~~181~~213,~~498~~882 in investing activities consisting of purchases of Silicon Oxide (SiOx) manufacturing equipment and ~~capitalized~~ capitalized patent costs.

For the ~~six~~nine months ended ~~June~~September 30, 2024, the Company used cash of $~~157~~190,~~834~~931 in investing activities consisting of capitalized patent costs.

Net Cash provided by Financing Activities

For the ~~six~~nine months ended ~~June~~September 30, 2025, the Company generated ~~cash~~ cash of $~~198~~628,~~415~~437 from financing activities. The Company received proceeds from warrant exercises of $~~241~~671,~~546~~568. These increases were offset by by repayment of short-term notes of $42,671.

For the ~~six~~nine months ended ~~June~~September 30, 2024, the Company generated cash of $37,~~954~~056,~~930~~000 from financing activities. The Company received proceeds from Private Placement financing and ~~convertible~~ convertible notes of $37,850,000 and $527,500, respectively. These increases were offset by repayment of short-term notes and repayment of related party advances of $~~424~~1,~~277~~329,712 and $911,091, respectively.

3536

Going Concern Considerations, Liquidity and Capital Resources

Since Solidion’s inception, the Company has experienced recurring net losses and has generated minimal sales. This raises substantial doubt about the Company’s ability to continue as a going concern. Management’s ability to fund our operations and capital expenditures depends on our ability to raise additional external capital. This is subject to our future operating performance and general economic, financial, competitive, legislative, regulatory, and other conditions, some of which are beyond our control. We are currently engaged in discussions with various financing counterparties to secure sufficient capital to meet our business needs for the foreseeable future. The Company plans to finance its operations with proceeds from the sale of equity securities, government grants and loans, or debt; however, there is no assurance that management’s plans to obtain additional debt, grants or equity financing will be successfully implemented or implemented on terms favorable to the Company.

As of ~~June~~September 30, 2025, we had an accumulated deficit of $~~106~~112,~~539~~891,~~088~~883. Additionally, $1,400,717 in NUBI transaction costs incurred at the Closing Date in connection with the Merger remain outstanding and are due within the next twelve months. During the ~~six~~nine months ended ~~June~~September 30, 2025, we incurred losses from operations totaling $46,~~919~~662,~~793~~693 and net cash used in operating activities of $3,~~255~~607,~~997~~781. We expect to continue to incur such losses for at least the next twelve (12) months.

Off-Balance Sheet Arrangements

At ~~June~~September 30, 2025, we have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.

We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or entered into any non-financial agreements involving assets.

Critical Accounting Estimates

We prepare our financial statements in accordance with U.S. generally accepted accounting principles, which require our management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.

We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our financial statement that require estimation but are not deemed critical, as defined above. There were no changes to the Company’s critical accounting estimates from those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2024.

Forward Purchase Agreement

The Company accounts for the forward purchase agreement as either equity-classified or liability-classified instruments based on an assessment of the Forward Purchase Agreement (“FPA”) specific terms and applicable authoritative guidance in FASB ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”), and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the FPA is a freestanding financial instrument pursuant to ASC 480, meets the definition of a liability pursuant to ASC 480, and whether the FPA meets all of the requirements for equity classification under ASC 815, including whether the FPA is indexed to the Company’s own common shares and whether the FPA holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of FPA issuance and as of each subsequent quarterly period end date while the FPA is outstanding.

For issued or modified FPA that meet all of the criteria for equity classification, the FPA is required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified FPAs that do not meet all of the criteria for equity classification, the FPA are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The Company accounts for outstanding FPA as liability-classified instrument.

The fair value of the FPA is Level 3. The determination of the fair value requires significant estimates and judgments. Please see Note 13 Fair Value Measurements to the financial statements for the significant assumptions and estimates.

Changes in the significant assumptions and estimates could materially impact the valuation and the amounts recorded in the financial statements.

3637

Recently Adopted Accounting Standards

Recently Issued Accounting Standards

Item 3. Quantitative and Qualitative Disclosures About Market Risk

This item is not applicable as we are a smaller reporting company.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based on an evaluation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of ~~June~~September 30, 2025, because of certain material weaknesses in our internal control over financial reporting, as further ~~described~~ described below.

Notwithstanding these material weaknesses, our management concluded that our consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows as of and for the periods presented in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”).

3738

Management’s Report on Internal Control Over Financial Reporting

Material Weaknesses

A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Management identified deficiencies in the principles associated with the control environment, risk assessment, control activities, information & communication, and monitoring components of internal control, based on the criteria established by the COSO framework, that constitute material weaknesses, either individually or in the aggregate as described below.

Control Environment: Solidion does not maintain a sufficient complement of qualified technical accounting and financial reporting personnel to perform control activities, including those related to complex and/or non-routine transactions. Additionally, Solidion did not implement sufficient segregation of duties within its financial reporting function in order to demonstrate independence and proper oversight. This material weakness contributed to the additional material weaknesses further described below.

Risk Assessment: Solidion did not design and implement an effective risk assessment based on the criteria established in the COSO framework. A material weakness, either individually or in the aggregate, was identified pertaining to (i) identifying, assessing, and communicating appropriate objectives; (ii) identifying and analyzing risks to achieve these objectives; and (iii) implementing an effective risk assessment to identify and assess changes in the business if such changes were to occur.

Control Activities: Solidion did not effectively design and implement control activities to support the operating effectiveness of controls to prevent and detect potential material errors based on the criteria established in the COSO framework. As a result, the following control deficiencies constitute material weaknesses, individually or in the aggregate: (i) ineffective controls related to the review and approval of journal entries and reconciliations, and (ii) a lack of appropriate accounting policies and procedures.

Information and Communication: We identified control deficiencies that constitute material weaknesses, either individually or in the aggregate, related to (i) internal communication of information, including objectives and responsibilities for internal control, necessary to support the functioning of internal control; and (ii) communicating relevant information to external parties timely.

Monitoring: Solidion did not maintain effective monitoring activities to determine whether the components of internal control over financial reporting were present and functioning based on the criteria established in the COSO framework.

Remediation Plans and Status

We are committed to maintaining a strong internal control environment and implementing measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated as soon as practicable. We plan to engage a third party to assist in our remediation efforts. We will design and implement a risk assessment process and establish processes and controls to support an effective control environment. These actions are intended to enable Solidion to enhance our monitoring of our internal controls over financial reporting as well as enhance required communication. In addition, we will design and implement controls to address material weaknesses in control activities including the proper review and approval of journal entries and reconciliations.

As Solidion continues to evaluate its internal controls, it may take additional remediation actions. The material weaknesses will be considered remediated when Solidion’s management designs and implements effective controls that operate for a sufficient period of time and management has concluded, through testing, that these controls are effective. Solidion’s management will monitor the effectiveness of its remediation plans and will make changes management determines to be appropriate.

Changes in Internal Control over Financial Reporting

There were no changes during the quarter ended ~~June~~September 30, 2025, in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3839

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

During the quarter ended ~~June~~September 30, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

3940

ITEM 6. [EXHIBITS]

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Exhibit No.		Description
3.1		Amended and Restated Certificate of Incorporation of Solidion Technology, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on February 8, 2024)
3.2		Amended and Restated Bylaws of Solidion Technology, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on February 8, 2024)
10.1*		Amendment to the Securities Purchase Agreement, dated as of October 21, 2025, by and among Bayside Project LLC, Madison Bond LLC and Solidion Technology, Inc.
10.2*		Lock-up Agreement, dated as of October 21, 2025, by and among Solidion Technology, Inc., Bayside Project LLC, Madison Bond LLC and Solidion Technology, Inc.
31.1*		Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14(a) under the Securities and Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14(a) under the Securities and Exchange Act of 1934, as amended., as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*		Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*	Filed herewith

4041

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Solidion Technology, Inc.
Dated: August 19, 2025	By:	/s/ Jaymes Winters
Dated: November 19, 2025	By:	/s/ Jaymes Winters
	Name:	Jaymes Winters
	Title:	Chief Executive Officer (Principal Executive Officer)

	Solidion Technology, Inc.
Dated: August 19, 2025	By:	/s/ Vlad Prantsevich
Dated: November 19, 2025	By:	/s/ Vlad Prantsevich
	Name:	Vlad Prantsevich
	Title:	Chief Financial Officer (Principal Accounting and Financial Officer)

4142

0.00 0.00 0001881551 false Q2 --12-31 0001881551 2025-01-01 2025-06-30 0001881551 2025-08-13 0001881551 2025-06-30 0001881551 2024-12-31 0001881551 us-gaap:RelatedPartyMember 2025-06-30 0001881551 us-gaap:RelatedPartyMember 2024-12-31 0001881551 2025-04-01 2025-06-30 0001881551 2024-04-01 2024-06-30 0001881551 2024-01-01 2024-06-30 0001881551 us-gaap:CommonStockMember 2024-12-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001881551 us-gaap:RetainedEarningsMember 2024-12-31 0001881551 sti:StockSubscriptionReceivableMember 2024-12-31 0001881551 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001881551 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001881551 sti:StockSubscriptionReceivableMember 2025-01-01 2025-03-31 0001881551 2025-01-01 2025-03-31 0001881551 us-gaap:CommonStockMember 2025-03-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001881551 us-gaap:RetainedEarningsMember 2025-03-31 0001881551 sti:StockSubscriptionReceivableMember 2025-03-31 0001881551 2025-03-31 0001881551 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001881551 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001881551 sti:StockSubscriptionReceivableMember 2025-04-01 2025-06-30 0001881551 us-gaap:CommonStockMember 2025-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001881551 us-gaap:RetainedEarningsMember 2025-06-30 0001881551 sti:StockSubscriptionReceivableMember 2025-06-30 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2023-12-31 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2023-12-31 0001881551 srt:ScenarioPreviouslyReportedMember sti:StockSubscriptionReceivableMember 2023-12-31 0001881551 srt:ScenarioPreviouslyReportedMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember us-gaap:CommonStockMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember us-gaap:RetainedEarningsMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember sti:StockSubscriptionReceivableMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember 2023-12-31 0001881551 us-gaap:CommonStockMember 2023-12-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 us-gaap:RetainedEarningsMember 2023-12-31 0001881551 sti:StockSubscriptionReceivableMember 2023-12-31 0001881551 2023-12-31 0001881551 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001881551 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001881551 sti:StockSubscriptionReceivableMember 2024-01-01 2024-03-31 0001881551 2024-01-01 2024-03-31 0001881551 us-gaap:CommonStockMember 2024-03-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001881551 us-gaap:RetainedEarningsMember 2024-03-31 0001881551 sti:StockSubscriptionReceivableMember 2024-03-31 0001881551 2024-03-31 0001881551 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001881551 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001881551 sti:StockSubscriptionReceivableMember 2024-04-01 2024-06-30 0001881551 us-gaap:CommonStockMember 2024-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001881551 us-gaap:RetainedEarningsMember 2024-06-30 0001881551 sti:StockSubscriptionReceivableMember 2024-06-30 0001881551 2024-06-30 0001881551 sti:MergerAgreementMember us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001881551 sti:MergerAgreementMember 2025-01-01 2025-06-30 0001881551 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001881551 2024-01-01 2024-12-31 0001881551 sti:MergerAgreementMember 2024-01-01 2024-12-31 0001881551 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001881551 sti:ConvertibleNotesMember 2025-01-01 2025-06-30 0001881551 2025-05-12 2025-05-12 0001881551 srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-06-30 0001881551 srt:RestatementAdjustmentMember 2024-01-01 2024-06-30 0001881551 sti:AsReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 sti:AsReportedMember us-gaap:RetainedEarningsMember 2023-12-31 0001881551 sti:AsReportedMember 2023-12-31 0001881551 sti:AsReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001881551 sti:AsReportedMember us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001881551 sti:AsReportedMember 2024-01-01 2024-06-30 0001881551 sti:AsReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001881551 sti:AsReportedMember us-gaap:RetainedEarningsMember 2024-06-30 0001881551 sti:AsReportedMember 2024-06-30 0001881551 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2023-12-31 0001881551 srt:RestatementAdjustmentMember 2023-12-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001881551 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001881551 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001881551 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001881551 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001881551 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2024-06-30 0001881551 srt:RestatementAdjustmentMember 2024-06-30 0001881551 sti:GlobalGrapheneGroupMember 2024-03-31 0001881551 us-gaap:PatentsMember 2025-06-30 0001881551 sti:OhioRDMember 2025-06-30 0001881551 sti:OhioRDMember 2024-12-31 0001881551 sti:ReverseStockSplitMember 2025-05-12 0001881551 sti:ReverseStockSplitMember 2025-05-12 2025-05-12 0001881551 us-gaap:BuildingMember 2025-06-30 0001881551 us-gaap:LeaseholdImprovementsMember 2025-06-30 0001881551 us-gaap:EquipmentMember 2025-06-30 0001881551 sti:HoldbackSharesMember 2024-01-01 2024-06-30 0001881551 sti:WarrantsPublicMember 2024-01-01 2024-06-30 0001881551 sti:WarrantsPrivateMember 2024-01-01 2024-06-30 0001881551 sti:WarrantsSeriesAMember 2024-01-01 2024-06-30 0001881551 sti:WarrantsSeriesBMember 2024-01-01 2024-06-30 0001881551 us-gaap:StockCompensationPlanMember 2024-01-01 2024-06-30 0001881551 sti:ForwardPurchaseAgreementAdditionalSharesMember 2024-01-01 2024-06-30 0001881551 sti:HBCEarnoutSharesMember 2024-01-01 2024-06-30 0001881551 sti:WarrantsSeriesBMember 2024-04-01 2024-06-30 0001881551 us-gaap:StockCompensationPlanMember 2024-04-01 2024-06-30 0001881551 sti:ConvertibleNotesMember 2024-04-01 2024-06-30 0001881551 sti:WarrantsSeriesAMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsSeriesCMember 2025-04-01 2025-06-30 0001881551 us-gaap:StockCompensationPlanMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsSeriesAMember 2025-01-01 2025-06-30 0001881551 sti:WarrantsSeriesBMember 2025-01-01 2025-06-30 0001881551 us-gaap:StockCompensationPlanMember 2025-01-01 2025-06-30 0001881551 sti:IPOWarrantsMember 2022-12-31 0001881551 sti:PrivatePlacementWarrantsMember 2022-12-31 0001881551 sti:HBCHoldbackSharesMember 2025-06-30 0001881551 sti:HBCShareholdersMember 2025-01-01 2025-06-30 0001881551 sti:HBCEarnoutArrangementMember 2025-06-30 0001881551 sti:HBCEarnoutArrangementMember 2025-01-01 2025-06-30 0001881551 sti:MergerMember 2024-01-01 2024-03-31 0001881551 sti:MergerMember sti:NubiaCommonStockMember 2024-01-01 2024-03-31 0001881551 sti:MergerMember sti:NubiaConvertibleNoteholdersMember 2024-01-01 2024-03-31 0001881551 sti:MergerMember sti:PredecessorHBCSharesMember 2024-01-01 2024-03-31 0001881551 sti:MergerMember 2024-01-01 2024-03-31 0001881551 sti:PredecessorHBCSharesMember 2024-03-31 0001881551 sti:SharesIssuedToShareholdersOfPredecessorHBCMember 2024-03-31 0001881551 2023-10-01 2024-03-31 0001881551 sti:SharedServiceAgreementMember 2025-01-01 2025-06-30 0001881551 sti:GlobalGrapheneGroupMember 2025-01-01 2025-06-30 0001881551 sti:GlobalGrapheneGroupMember 2024-01-01 2024-12-31 0001881551 sti:MachFMMember 2025-06-30 0001881551 us-gaap:RelatedPartyMember sti:GlobalGrapheneGroupMember 2025-01-01 2025-06-30 0001881551 sti:MachFMMember 2024-01-01 2024-12-31 0001881551 sti:TaxLienMember 2025-01-01 2025-06-30 0001881551 sti:HBCHoldbackSharesMember 2025-01-01 2025-06-30 0001881551 sti:G3HoldbackSharesMember 2025-01-01 2025-06-30 0001881551 us-gaap:GeneralAndAdministrativeExpenseMember 2025-04-01 2025-06-30 0001881551 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-06-30 0001881551 us-gaap:CommonStockMember 2025-06-30 0001881551 us-gaap:CommonStockMember 2024-12-31 0001881551 us-gaap:PrivatePlacementMember 2024-03-13 2024-03-13 0001881551 2024-03-13 2024-03-13 0001881551 sti:SeriesAAndBWarrantsMember 2024-03-13 2024-03-13 0001881551 us-gaap:PrivatePlacementMember 2025-01-01 2025-06-30 0001881551 us-gaap:PrivatePlacementMember 2024-08-30 2024-08-30 0001881551 2024-08-30 2024-08-30 0001881551 us-gaap:SeriesCPreferredStockMember 2024-08-30 0001881551 us-gaap:PrivatePlacementMember 2025-06-30 0001881551 sti:IPOWarrantsMember 2022-12-01 2022-12-31 0001881551 sti:IPOWarrantsMember 2025-01-01 2025-06-30 0001881551 srt:MinimumMember sti:IPOWarrantsMember 2025-01-01 2025-06-30 0001881551 srt:MaximumMember sti:IPOWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:PrivateWarrantsMember 2022-01-01 2022-12-31 0001881551 sti:PrivateWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:SeriesAWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:SeriesBWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:SeriesAAndBWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:SeriesAWarrantsMember 2025-04-01 2025-06-30 0001881551 sti:SeriesAWarrantsMember 2025-06-30 0001881551 sti:SeriesBWarrantsMember 2025-06-30 0001881551 sti:SeriesAAndBWarrantsMember 2025-06-30 0001881551 sti:SeriesCWarrantsMember sti:MonteCarloMember 2025-01-01 2025-06-30 0001881551 sti:SeriesDWarrantsMember sti:MonteCarloMember 2025-01-01 2025-06-30 0001881551 sti:WarrantsSeriesCAndDMember 2025-01-01 2025-06-30 0001881551 sti:SeriesCWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:SeriesDWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:SeriesCWarrantsMember 2025-04-01 2025-06-30 0001881551 sti:SeriesCWarrantsMember 2025-06-30 0001881551 sti:SeriesDWarrantsMember 2025-06-30 0001881551 sti:ForwardPurchaseAgreementMember 2025-01-01 2025-06-30 0001881551 us-gaap:CommonClassAMember sti:ForwardPurchaseAgreementMember 2025-06-30 0001881551 sti:ForwardPurchaseAgreementMember 2025-06-30 0001881551 sti:NUBISharesMember sti:ForwardPurchaseAgreementMember 2025-06-30 0001881551 2024-02-02 2024-02-02 0001881551 sti:ForwardPurchaseAgreementMember 2024-02-02 2024-02-02 0001881551 sti:ForwardPurchaseAgreementMember 2024-02-02 0001881551 sti:ForwardPurchaseAgreementMember 2024-01-17 2024-01-17 0001881551 sti:ForwardPurchaseAgreementMember 2024-03-22 2024-03-22 0001881551 sti:ForwardPurchaseAgreementMember 2024-06-11 2024-06-11 0001881551 sti:FPAShareMember 2025-01-01 2025-06-30 0001881551 sti:ForwardPurchaseAgreementMember 2024-08-29 2024-08-29 0001881551 2024-08-29 2024-08-29 0001881551 sti:FPAAmendmentAndResolutionOfLawsuitMember us-gaap:CommonStockMember 2025-06-30 0001881551 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001881551 us-gaap:CommonStockMember 2024-08-29 0001881551 sti:NonRedemptionAgreementMember 2025-04-01 2025-06-30 0001881551 sti:BackstopInvestorMember 2024-02-02 0001881551 2024-02-02 0001881551 2024-10-31 2024-10-31 0001881551 2024-09-30 2024-09-30 0001881551 sti:ConvertibleNotesMember 2024-01-01 2024-12-31 0001881551 sti:ConvertibleNotesMember 2025-01-01 2025-06-30 0001881551 sti:ConvertibleNotesMember 2025-06-30 0001881551 sti:PromissoryNoteMember sti:EFHuttonMember 2024-02-01 0001881551 sti:PromissoryNoteMember 2024-02-01 2024-02-01 0001881551 sti:PromissoryNoteMember 2025-03-01 0001881551 sti:PromissoryNoteMember sti:EFHuttonMember 2025-06-30 0001881551 sti:EFHuttonMember 2025-01-01 2025-06-30 0001881551 sti:EFHuttonMember 2024-01-01 2024-12-31 0001881551 sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-04-29 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-04-29 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-04-29 2024-04-29 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-11-12 0001881551 sti:PromissoryNoteMember 2024-11-12 2024-11-12 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember us-gaap:SubsequentEventMember 2025-08-04 0001881551 sti:PromissoryNoteMember us-gaap:SubsequentEventMember 2025-08-04 2025-08-04 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001881551 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001881551 srt:MinimumMember 2025-01-01 2025-06-30 0001881551 srt:MaximumMember 2025-01-01 2025-06-30 0001881551 srt:ExecutiveOfficerMember 2025-01-01 2025-06-30 0001881551 sti:MonteCarloMember 2025-01-01 2025-06-30 0001881551 sti:SeriesBWarrantsMember 2024-04-01 2024-06-30 0001881551 sti:SeriesBWarrantsMember 2024-01-01 2024-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:CommonStockMember 2025-06-30 0001881551 sti:SeriesBWarrantsMember us-gaap:CommonStockMember 2025-06-30 0001881551 sti:WarrantsSeriesAAndBMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsSeriesAAndBMember 2025-01-01 2025-06-30 0001881551 sti:HBCEarnoutSharesMember 2025-06-30 0001881551 sti:HBCEarnoutSharesMember 2025-01-01 2025-06-30 0001881551 sti:AwardsWithMarketBasedConditionsMember 2025-06-30 0001881551 sti:AwardsWithMarketBasedConditionsMember 2025-01-01 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember 2024-12-31 0001881551 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-06-30 0001881551 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001881551 us-gaap:MeasurementInputSharePriceMember 2025-06-30 0001881551 us-gaap:MeasurementInputSharePriceMember 2024-12-31 0001881551 us-gaap:MeasurementInputExpectedTermMember 2025-06-30 0001881551 us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001881551 us-gaap:MeasurementInputPriceVolatilityMember 2025-06-30 0001881551 us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001881551 us-gaap:MeasurementInputExpectedDividendRateMember 2025-06-30 0001881551 us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-06-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-06-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-06-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-06-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-06-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-06-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-06-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-06-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-06-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-06-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-06-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-06-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-04-01 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-04-01 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-04-01 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001881551 sti:BeneschNoteMember us-gaap:SubsequentEventMember 2025-08-04 0001881551 sti:BeneschNoteMember us-gaap:SubsequentEventMember 2025-08-04 2025-08-04 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 0.00 0.00 0001881551 false Q3 --12-31 0001881551 2025-01-01 2025-09-30 0001881551 2025-11-19 0001881551 2025-09-30 0001881551 2024-12-31 0001881551 us-gaap:RelatedPartyMember 2025-09-30 0001881551 us-gaap:RelatedPartyMember 2024-12-31 0001881551 2025-07-01 2025-09-30 0001881551 2024-07-01 2024-09-30 0001881551 2024-01-01 2024-09-30 0001881551 us-gaap:CommonStockMember 2025-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001881551 us-gaap:RetainedEarningsMember 2025-06-30 0001881551 sti:StockSubscriptionReceivableMember 2025-06-30 0001881551 2025-06-30 0001881551 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001881551 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001881551 sti:StockSubscriptionReceivableMember 2025-07-01 2025-09-30 0001881551 us-gaap:CommonStockMember 2025-09-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001881551 us-gaap:RetainedEarningsMember 2025-09-30 0001881551 sti:StockSubscriptionReceivableMember 2025-09-30 0001881551 us-gaap:CommonStockMember 2024-12-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001881551 us-gaap:RetainedEarningsMember 2024-12-31 0001881551 sti:StockSubscriptionReceivableMember 2024-12-31 0001881551 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001881551 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001881551 sti:StockSubscriptionReceivableMember 2025-01-01 2025-09-30 0001881551 us-gaap:CommonStockMember 2024-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001881551 us-gaap:RetainedEarningsMember 2024-06-30 0001881551 sti:StockSubscriptionReceivableMember 2024-06-30 0001881551 2024-06-30 0001881551 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001881551 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001881551 sti:StockSubscriptionReceivableMember 2024-07-01 2024-09-30 0001881551 us-gaap:CommonStockMember 2024-09-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001881551 us-gaap:RetainedEarningsMember 2024-09-30 0001881551 sti:StockSubscriptionReceivableMember 2024-09-30 0001881551 2024-09-30 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2023-12-31 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2023-12-31 0001881551 srt:ScenarioPreviouslyReportedMember sti:StockSubscriptionReceivableMember 2023-12-31 0001881551 srt:ScenarioPreviouslyReportedMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember us-gaap:CommonStockMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember us-gaap:RetainedEarningsMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember sti:StockSubscriptionReceivableMember 2023-12-31 0001881551 sti:RetroactiveApplicationOfRecapitalizationMember 2023-12-31 0001881551 us-gaap:CommonStockMember 2023-12-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 us-gaap:RetainedEarningsMember 2023-12-31 0001881551 sti:StockSubscriptionReceivableMember 2023-12-31 0001881551 2023-12-31 0001881551 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001881551 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001881551 sti:StockSubscriptionReceivableMember 2024-01-01 2024-09-30 0001881551 us-gaap:CommonStockMember sti:MergerAgreementMember 2025-01-01 2025-09-30 0001881551 sti:MergerAgreementMember 2025-01-01 2025-09-30 0001881551 sti:MergerAgreementMember 2025-10-09 2025-10-09 0001881551 2024-01-01 2024-12-31 0001881551 sti:MergerAgreementMember 2024-01-01 2024-12-31 0001881551 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001881551 sti:ConvertibleNotesMember 2025-01-01 2025-09-30 0001881551 2025-05-12 2025-05-12 0001881551 srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-09-30 0001881551 srt:RestatementAdjustmentMember 2024-01-01 2024-09-30 0001881551 sti:AsReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 sti:AsReportedMember us-gaap:RetainedEarningsMember 2023-12-31 0001881551 sti:AsReportedMember 2023-12-31 0001881551 sti:AsReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001881551 sti:AsReportedMember us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001881551 sti:AsReportedMember 2024-01-01 2024-09-30 0001881551 sti:AsReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001881551 sti:AsReportedMember us-gaap:RetainedEarningsMember 2024-09-30 0001881551 sti:AsReportedMember 2024-09-30 0001881551 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001881551 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2023-12-31 0001881551 srt:RestatementAdjustmentMember 2023-12-31 0001881551 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001881551 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001881551 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001881551 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2024-09-30 0001881551 srt:RestatementAdjustmentMember 2024-09-30 0001881551 sti:GlobalGrapheneGroupMember 2024-03-31 0001881551 us-gaap:PatentsMember 2025-09-30 0001881551 sti:ReverseStockSplitMember 2025-05-12 0001881551 sti:ReverseStockSplitMember 2025-05-12 2025-05-12 0001881551 2025-01-01 2025-03-31 0001881551 us-gaap:BuildingMember 2025-09-30 0001881551 us-gaap:LeaseholdImprovementsMember 2025-09-30 0001881551 us-gaap:EquipmentMember 2025-09-30 0001881551 sti:HoldbackSharesMember 2024-01-01 2024-09-30 0001881551 sti:WarrantsPublicMember 2024-01-01 2024-09-30 0001881551 sti:WarrantsPrivateMember 2024-01-01 2024-09-30 0001881551 sti:WarrantsSeriesAMember 2024-01-01 2024-09-30 0001881551 sti:WarrantsSeriesBMember 2024-01-01 2024-09-30 0001881551 sti:WarrantsSeriesCMember 2024-01-01 2024-09-30 0001881551 sti:WarrantsSeriesDMember 2024-01-01 2024-09-30 0001881551 us-gaap:StockCompensationPlanMember 2024-01-01 2024-09-30 0001881551 sti:ArborLakeStrategicCooperationConsultingAgreementMember 2024-01-01 2024-09-30 0001881551 sti:HBCEarnoutSharesMember 2024-01-01 2024-09-30 0001881551 sti:HoldbackSharesMember 2025-07-01 2025-09-30 0001881551 sti:WarrantsPublicMember 2025-07-01 2025-09-30 0001881551 sti:WarrantsPrivateMember 2025-07-01 2025-09-30 0001881551 sti:WarrantsSeriesAMember 2025-07-01 2025-09-30 0001881551 sti:WarrantsSeriesCMember 2025-07-01 2025-09-30 0001881551 sti:WarrantsSeriesDMember 2025-07-01 2025-09-30 0001881551 us-gaap:StockCompensationPlanMember 2025-07-01 2025-09-30 0001881551 sti:StockbasedCompensationWarrantsMember 2025-07-01 2025-09-30 0001881551 sti:ArborLakeStrategicCooperationConsultingAgreementMember 2025-07-01 2025-09-30 0001881551 sti:HBCEarnoutSharesMember 2025-07-01 2025-09-30 0001881551 sti:WarrantsSeriesAMember 2025-01-01 2025-09-30 0001881551 sti:WarrantsSeriesCMember 2025-01-01 2025-09-30 0001881551 us-gaap:StockCompensationPlanMember 2025-01-01 2025-09-30 0001881551 sti:IPOWarrantsMember 2022-12-31 0001881551 sti:PrivatePlacementWarrantsMember 2022-12-31 0001881551 sti:HBCHoldbackSharesMember 2025-09-30 0001881551 sti:HBCShareholdersMember 2025-01-01 2025-09-30 0001881551 us-gaap:MeasurementInputSharePriceMember 2025-09-30 0001881551 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-30 0001881551 us-gaap:MeasurementInputPriceVolatilityMember 2025-09-30 0001881551 us-gaap:MeasurementInputExpectedDividendRateMember 2025-09-30 0001881551 us-gaap:MeasurementInputExpectedTermMember 2025-09-30 0001881551 sti:HBCEarnoutArrangementMember 2025-01-01 2025-09-30 0001881551 sti:MergerMember 2024-01-01 2024-03-31 0001881551 sti:MergerMember sti:NubiaCommonStockMember 2024-01-01 2024-03-31 0001881551 sti:MergerMember sti:NubiaConvertibleNoteholdersMember 2024-01-01 2024-03-31 0001881551 sti:MergerMember sti:PredecessorHBCSharesMember 2024-01-01 2024-03-31 0001881551 sti:MergerMember 2024-01-01 2024-03-31 0001881551 sti:PredecessorHBCSharesMember 2024-03-31 0001881551 sti:SharesIssuedToShareholdersOfPredecessorHBCMember 2024-03-31 0001881551 2024-01-01 2024-03-31 0001881551 sti:SharedServicesAgreementMember 2025-09-30 0001881551 sti:SharedServicesAgreementMember 2024-12-31 0001881551 sti:GlobalGrapheneGroupMember 2025-01-01 2025-09-30 0001881551 sti:GlobalGrapheneGroupMember 2024-01-01 2024-12-31 0001881551 sti:MachFMMember 2025-09-30 0001881551 us-gaap:RelatedPartyMember sti:GlobalGrapheneGroupMember 2025-01-01 2025-09-30 0001881551 sti:MachFMMember 2024-01-01 2024-12-31 0001881551 sti:TaxLienMember 2025-01-01 2025-09-30 0001881551 us-gaap:SubsequentEventMember 2025-11-30 0001881551 sti:HBCHoldbackSharesMember 2025-01-01 2025-09-30 0001881551 sti:G3HoldbackSharesMember 2025-01-01 2025-09-30 0001881551 us-gaap:GeneralAndAdministrativeExpenseMember 2025-07-01 2025-09-30 0001881551 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-09-30 0001881551 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2025-10-24 2025-10-24 0001881551 us-gaap:CommonStockMember 2025-09-30 0001881551 us-gaap:CommonStockMember 2024-12-31 0001881551 us-gaap:PrivatePlacementMember 2024-03-13 2024-03-13 0001881551 2024-03-13 2024-03-13 0001881551 sti:SeriesAAndBWarrantsMember 2024-03-13 2024-03-13 0001881551 us-gaap:PrivatePlacementMember 2025-01-01 2025-09-30 0001881551 us-gaap:PrivatePlacementMember 2024-08-30 2024-08-30 0001881551 2024-08-30 2024-08-30 0001881551 us-gaap:SeriesCPreferredStockMember 2024-08-30 0001881551 us-gaap:PrivatePlacementMember 2025-09-30 0001881551 sti:IPOWarrantsMember 2022-12-01 2022-12-31 0001881551 sti:IPOWarrantsMember 2025-01-01 2025-09-30 0001881551 srt:MinimumMember sti:IPOWarrantsMember 2025-01-01 2025-09-30 0001881551 srt:MaximumMember sti:IPOWarrantsMember 2025-01-01 2025-09-30 0001881551 sti:PrivateWarrantsMember 2022-01-01 2022-12-31 0001881551 sti:PrivateWarrantsMember 2025-01-01 2025-09-30 0001881551 sti:SeriesAWarrantsMember 2025-01-01 2025-09-30 0001881551 sti:SeriesBWarrantsMember 2025-01-01 2025-09-30 0001881551 sti:SeriesAAndBWarrantsMember 2025-01-01 2025-09-30 0001881551 2025-05-14 0001881551 us-gaap:WarrantMember 2025-05-14 0001881551 sti:SeriesAWarrantsMember 2024-07-01 2024-09-30 0001881551 sti:SeriesBWarrantsMember 2024-01-01 2024-09-30 0001881551 sti:SeriesAWarrantsMember 2025-09-30 0001881551 sti:SeriesBWarrantsMember 2025-09-30 0001881551 sti:SeriesAAndBWarrantsMember 2025-09-30 0001881551 sti:SeriesCWarrantsMember sti:MonteCarloMember 2025-01-01 2025-09-30 0001881551 sti:SeriesDWarrantsMember 2025-01-01 2025-09-30 0001881551 sti:WarrantsSeriesCAndDMember 2025-01-01 2025-09-30 0001881551 sti:SeriesCWarrantsMember 2025-01-01 2025-09-30 0001881551 us-gaap:WarrantMember 2025-07-01 2025-09-30 0001881551 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001881551 sti:SeriesCWarrantsMember 2024-07-01 2024-09-30 0001881551 sti:SeriesDWarrantsMember 2024-01-01 2024-09-30 0001881551 sti:SeriesCWarrantsMember 2025-09-30 0001881551 sti:SeriesDWarrantsMember 2025-09-30 0001881551 2025-10-08 2025-10-08 0001881551 sti:ForwardPurchaseAgreementMember 2025-01-01 2025-09-30 0001881551 us-gaap:CommonClassAMember sti:ForwardPurchaseAgreementMember 2025-09-30 0001881551 sti:ForwardPurchaseAgreementMember 2025-09-30 0001881551 sti:NUBISharesMember sti:ForwardPurchaseAgreementMember 2025-09-30 0001881551 2024-02-02 2024-02-02 0001881551 2024-02-02 0001881551 sti:ForwardPurchaseAgreementMember 2024-02-02 2024-02-02 0001881551 sti:ForwardPurchaseAgreementMember 2024-02-02 0001881551 sti:ForwardPurchaseAgreementMember 2024-01-17 2024-01-17 0001881551 sti:ForwardPurchaseAgreementMember 2024-03-22 2024-03-22 0001881551 sti:ForwardPurchaseAgreementMember 2024-06-11 2024-06-11 0001881551 sti:FPAShareMember 2025-01-01 2025-09-30 0001881551 sti:MonteCarloMember 2025-09-30 0001881551 sti:ForwardPurchaseAgreementMember 2024-08-29 2024-08-29 0001881551 2024-08-29 2024-08-29 0001881551 2024-08-29 0001881551 sti:FPAAmendmentAndResolutionOfLawsuitMember us-gaap:CommonStockMember 2025-09-30 0001881551 sti:MeteoraSharesMember 2024-08-29 0001881551 sti:ForwardPurchaseAgreementMember 2024-07-01 2024-09-30 0001881551 sti:NonRedemptionAgreementMember 2025-01-01 2025-09-30 0001881551 sti:BackstopInvestorMember 2024-02-02 0001881551 2024-03-31 0001881551 2024-10-31 2024-10-31 0001881551 2024-09-30 2024-09-30 0001881551 sti:ConvertibleNotesMember 2024-01-01 2024-12-31 0001881551 sti:ConvertibleNotesMember 2025-01-01 2025-09-30 0001881551 sti:ConvertibleNotesMember 2025-09-30 0001881551 sti:PromissoryNoteMember sti:EFHuttonMember 2024-02-01 0001881551 sti:PromissoryNoteMember 2024-02-01 2024-02-01 0001881551 sti:PromissoryNoteMember 2025-03-01 0001881551 sti:PromissoryNoteMember sti:EFHuttonMember 2025-09-30 0001881551 sti:EFHuttonMember 2025-01-01 2025-09-30 0001881551 sti:EFHuttonMember 2024-01-01 2024-12-31 0001881551 sti:PromissoryNoteMember 2025-01-01 2025-09-30 0001881551 sti:PromissoryNoteMember 2024-01-01 2024-12-31 0001881551 sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-04-29 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-04-29 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-04-29 2024-04-29 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-11-12 0001881551 sti:PromissoryNoteMember 2024-11-12 2024-11-12 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2025-08-04 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2025-08-04 2025-08-04 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2025-01-01 2025-09-30 0001881551 sti:PromissoryNoteMember sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-01-01 2024-12-31 0001881551 sti:BeneschFriedlanderCoplanAronoffLLPMember 2025-01-01 2025-09-30 0001881551 sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-01-01 2024-12-31 0001881551 sti:PromissoryNoteMember sti:GreatPointCapitalLLCMember 2025-10-29 0001881551 sti:PromissoryNoteMember sti:GreatPointCapitalLLCMember 2025-10-29 2025-10-29 0001881551 sti:PromissoryNoteMember 2025-09-30 0001881551 2025-07-04 2025-07-04 0001881551 sti:UnrestrictedCommonStockAwardsMember 2024-07-01 2024-09-30 0001881551 sti:UnrestrictedCommonStockAwardsMember 2024-01-01 2024-09-30 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2025-09-30 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001881551 us-gaap:WarrantMember 2025-07-01 2025-09-30 0001881551 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001881551 srt:MinimumMember 2025-01-01 2025-09-30 0001881551 srt:MaximumMember 2025-01-01 2025-09-30 0001881551 srt:ExecutiveOfficerMember 2025-01-01 2025-09-30 0001881551 sti:AwardsWithMarketBasedConditionsMember 2024-12-31 0001881551 sti:AwardsWithMarketBasedConditionsMember 2025-01-01 2025-09-30 0001881551 sti:AwardsWithMarketBasedConditionsMember 2025-09-30 0001881551 sti:MonteCarloMember 2025-01-01 2025-09-30 0001881551 sti:ForwardPurchaseAgreementMember 2025-09-30 0001881551 sti:ForwardPurchaseAgreementMember 2024-07-01 2024-09-30 0001881551 sti:SeriesAAndBWarrantsMember 2025-07-01 2025-09-30 0001881551 sti:SeriesAAndBWarrantsMember 2025-01-01 2025-09-30 0001881551 sti:SeriesDWarrantsMember sti:MonteCarloMember 2025-01-01 2025-09-30 0001881551 us-gaap:WarrantMember sti:MonteCarloMember 2025-07-01 2025-09-30 0001881551 us-gaap:WarrantMember sti:MonteCarloMember 2025-01-01 2025-09-30 0001881551 sti:WarrantsSeriesCAndDMember 2024-07-01 2024-09-30 0001881551 sti:WarrantsSeriesCAndDMember 2024-01-01 2024-09-30 0001881551 us-gaap:MeasurementInputQuotedPriceMember 2025-09-30 0001881551 us-gaap:MeasurementInputOptionVolatilityMember 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember 2024-12-31 0001881551 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001881551 us-gaap:MeasurementInputSharePriceMember 2024-12-31 0001881551 us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001881551 us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001881551 us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-03-15 0001881551 sti:SeriesBWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-03-15 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-09-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-09-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-09-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-09-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-09-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-08-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-08-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-09-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-09-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-09-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-09-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-09-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-09-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-09-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-09-30 0001881551 sti:SeriesCWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-09-30 0001881551 sti:SeriesDWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-04-01 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-07-01 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-04-01 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-07-01 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-04-01 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-07-01 2025-09-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:WarrantsSeriesCAndDMember us-gaap:FairValueMeasurementsRecurringMember 2025-09-30 0001881551 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-10-23 0001881551 sti:GlobalGrapheneGroupIncMember us-gaap:SubsequentEventMember 2025-10-09 2025-10-09 0001881551 us-gaap:SubsequentEventMember 2025-10-09 2025-10-09 0001881551 us-gaap:CommonStockMember 2025-10-09 0001881551 2025-10-09 0001881551 sti:PromissoryNoteMember sti:GreatPointCapitalLLCMember us-gaap:SubsequentEventMember 2025-10-29 0001881551 sti:PromissoryNoteMember sti:GreatPointCapitalLLCMember us-gaap:SubsequentEventMember 2025-10-29 2025-10-29 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Filing Compare · Solidion Technology Inc.